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Human rhinovirus (HRV) is responsible for the majority of common cold infections and asthma 
exacerbations. HRV predominantly replicates in the epithelial cells of the upper airway, where 
common cold symptoms are produced. However, HRV also enters the lower airway, 
encountering the epithelial cells and alveolar macrophages thought to produce inflammatory 
responses during HRV-induced asthma exacerbations. Notably, alveolar macrophages release 
inflammatory mediators such as MCP1/CCL2 and RANTES/CCL5 in response to HRV despite 
the fact that limited if any HRV replication occurs in these cells. The present study seeks to 
address the mechanism by which alveolar macrophages are susceptible but not permissive to 
HRV replication and to identify the step in the HRV replication cycle that restricts HRV to 
abortive replication in macrophages. Evidence presented herein demonstrates that major-group 
(ICAM-1 tropic) HRV replicate with limited success in cell line-derived macrophages, whereas 
minor-group (LDLR tropic) HRV do not replicate in these monocyte-lineage cells. In contrast, 
neither major- nor minor-group HRV replicate in primary human PBMC-derived macrophages. 
Capsid swap experiments demonstrated that difference in replicative capacity between major- 
and minor-group HRV is mediated at the level of permissiveness rather than susceptibility. RNA-
Seq gene expression studies identified candidate host genes that may act to regulate HRV 
replication. These RNA-Seq studies also revealed positive- and negative-sense HRV RNA 
genomes in monocyte-lineage cells, suggesting that abortive HRV replication takes place within 
them. Overexpressing interferon-stimulated genes (ISGs) implicated in restricting the replication 
of poliovirus did not affect the accumulation of HRV RNA. Further study will continue to 
investigate the differences between major- and minor-group HRV responsible for differential 
replication success in cell-line derived macrophages and characterize the point(s) in the HRV 
replication cycle at which replication is blocked in primary macrophages. The ultimate goals of 
these studies are to reveal vulnerabilities in the HRV replication cycle and to identify host factors 
whose expression might be pharmacologically altered to attenuate HRV infection, thereby 
providing novel treatment options for controlling the common cold and HRV-induced asthma 
exacerbations.
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Chapter 1 – Introduction
Basic HRV Biology
Human rhinoviruses (HRV) are the major etiologic agent of the common cold, and the 
biology of their replication makes these viruses uniquely well suited to producing acute 
infections of the respiratory tract. Whereas these infections are usually mild, they can have 
important health implications for those with underlying conditions such as COPD and asthma. 
Although the association of HRV with asthma exacerbation is well documented at the 
macroscopic level of airway inflammation and remodeling, the molecular basis for HRV-induced 
asthma exacerbation is not well understood; this knowledge gap provides the context for the 
body of work discussed here.
HRV are members of the genus enterovirus, in the virus family picornaviridae, a family 
of positive-sense RNA viruses. Although rhinovirus infections are generally mild, producing 
symptoms of the common cold, other salient members of the enterovirus genus, such as 
poliovirus, are capable of producing severe pathology in otherwise healthy individuals. The 
picornaviridae possess purely proteinaceous and nearly spherical icosahedral capsids measuring 
approximately 20-30 nm in diameter. The HRV icosahedral capsid, made up of a repeating 
pattern of four structural proteins termed VP1-VP4, surrounds a single-stranded, host 
mRNA-like, positive-sense viral RNA genome approximately 7.5 kilobases long that encodes 12 
functional viral proteins (1). Notably, the exact mechanisms of the rhinoviral replication 
machinery have not been fully worked out; however, mechanisms of replication are strongly 
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conserved within the enterovirus genus, and these are assumed to function similarly for HRV. 
The replication machinery of poliovirus has been studied in extensive detail, and provides the 
basis for most of our understanding of HRV replication mechanisms.
The host mRNA-like viral RNA contained within the HRV virion is immediately ready 
for translation into protein upon entering the cytoplasm of the host cell. This host mRNA-like 
molecule contains a single, long open reading frame surrounded by extensively structured 5’ and 
3’ untranslated regions (Figure 1). However, the viral RNA differs from host mRNA in a few key  
ways that allow it to be preferentially translated in host cells. Most host mRNA contains a 
methylated cap at its 5’ end that facilitates the entry of the host mRNA into the translational 
apparatus; the 5’ methyl cap is recognized by the small subunit of the ribosome, and the binding 
of this cap recruits the large ribosomal subunit during the initial steps of translation. In the HRV 
host mRNA-like genome, there 
is no 5’ methyl cap. However, 
the HRV RNA does contain an 
alternative structure to the 5’ 
methyl cap that allows for the 
HRV RNA to initiate 
translation within the ribosome. 
The alternative structure used 
by HRV is described as an 
internal ribosome entry site 
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Figure 1. HRV protein processing. The HRV positive-sense 
mRNA-like genome is immediately translated upon its 
introduction to the cytoplasm. The mRNA molecule encodes a 
single open reading frame that is co-translationally processed 
by  HRV proteases 2A and 3C, whose cleavage sites are 
represented in red and blue, respectively. Cleaved effector 
proteins then establish the necessary  microenvironment for 
the rest of the HRV replication cycle.
Figure credit: Principles of Virology: Molecular Biology, 
Pathogenesis, and Control of Animal Viruses, 2nd Edition 
(2003).
(IRES). The IRES represents a portion of the HRV genome with extensive secondary structure 
that is able to mimic the function of the host mRNA 5’ methyl cap. In order to preferentially 
translate its own genetic information, HRV has evolved a protease activity that cleaves the host 
cellular machinery essential in translating 5’ methyl-capped mRNA, namely the host factor 
eIF4G (2). Notably, IRES-mediated translation is not affected by this protease activity, and in 
fact HRV co-opts a cleavage product of eIF4G that preferentially binds to viral RNA and 
facilitates its translation (3). Thus, the virus is able to downregulate host protein synthesis while 
sustaining production of its own proteins.
Although IRES-mediated translation produces a large amount of viral protein, the viral 
protein produced by preferential translation of the HRV RNA genome is not immediately 
available in a functional form. Because the HRV genome is made up of only one continuous 
RNA molecule and only one open reading frame, only one continuous protein is synthesized 
when this RNA molecule is translated. The translation product is polycistronic, made up of the 
protein products of a number of rhinovirus genes. In order for the products of these individual 
genes to be functional, they must be cleaved out of the polyprotein. Cleavage from the 
polyprotein is accomplished co- and post-translationally by protease activity inherent to the 
polyprotein itself; the polyprotein contains proteases that are able to cleave themselves out and 
separate the rest of the polyprotein into its 12 functional protein units (4). The primary viral 
proteases responsible for autoproteolytic cleavage in HRV are 2A and 3C (5).
3
Once the polyprotein has been 
fully synthesized and proteolytically 
processed, the various viral effector 
proteins begin to orchestrate the 
production of progeny virus particles; 
the full HRV replication cycle is 
depicted schematically in Figure 2. The 
rhinoviral RNA replicase protein 3D, 
also known as RNA-dependent 
RNA-polymerase (RdRp), eventually 
induces the production of a large 
quantity of viral RNA. The RdRp first 
produces a negative-sense RNA 
template and uses this template to 
produce a large excess of new, 
positive-sense viral RNA strands. In an 
infected permissive cell, enteroviral 
strand replication results in a positive- 
to negative-strand ratio of 
approximately 100:1, but this ratio can 
be as high as 1000:1 (6,7). Viral RNA 
production occurs on the surface of 
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Figure 2. HRV replication cycle. HRV replication 
begins by  (1) attachment of the virus particle to a 
susceptible host cell expressing the proper receptor. 
Once attached, the virion is endocytosed and the 
viral capsid uncoats (2), injecting the mRNA-like 
positive-sense viral RNA molecule in the cell. Upon 
its arrival in the cytoplasm, the viral genome is 
immediately  translated by  host ribosomes (3). As the 
viral RNA molecule is translated, viral proteases act 
in cis and in trans to co- and post-translationally 
process the viral protein (4). Effector proteins from 
the P2 and P3 regions of the viral genome facilitate 
negative-strand synthesis on double-membraned, 
autophagosome-like vesicular structures (5), which 
immediately  precedes positive-strand synthesis (6). 
Additional translation (7) is then followed by 
packaging of positive-sense viral RNAs into maturing 
virions (8). The newly  generated virions are then 
released from the cell (9), usually by lysis.
Figure credit: Principles of Virology: Molecular 
Biology, Pathogenesis, and Control of Animal 
Viruses, 2nd Edition (2003).
double-membraned, endoplasmic reticulum-derived, autophagosome-like vesicles called 
“replication factories” that are recruited to the viral replication machinery by specific viral 
effector proteins, including 2B, 2C, the 2BC precursor, 3A and the 3AB precursor (8). The 2B, 
2C, and 2BC precursor proteins are not directly involved in replication of viral RNA, but rather 
are required for recruiting the membranes required in forming the replication factories. These 
proteins also serve a structural role, providing a molecular scaffold for RNA replication along 
with the membranous vesicles. The 3AB protein’s role is much more active (9); after 3AB is 
cleaved by the 3C protease, released 3B protein, also known as VPg, interacts with the cis-acting 
replication element (cre) present in a structured portion of HRV RNA, where it joins with the 3D 
polymerase to serve as a primer and direct templated RNA synthesis (10-12). The VPg protein is 
also covalently attached to the 5’ end of viral RNA (13).
Once new viral RNAs are produced, protein 2C facilitates encapsidation of the virus 
(14). Following the assembly of viral RNA and newly translated viral protein into a large 
quantity of virions, the host cell may lyse, sending forth a host of virus particles that can carry 
out further infection. Notably, many mature HRV virions are not actually infectious; the 
particle/plaque-forming-unit ratio for HRV, like that of other picornaviruses, is quite high. The 
elevated prevalence of defective HRV virions can largely be explained by the error-prone nature 
of RdRp activity; since the viral polymerase lacks proofreading ability, lethal mutations occur in 
the HRV genome at a high frequency, with new mutations occurring as often as one or two 
misincorporations per genome replication event (15). However, virions can also be defective for 
a variety of other reasons, such as incorrect packaging of viral RNA.
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Rhinovirus Pathology
HRV predominantly infects epithelial cells of the upper respiratory tract, particularly in 
the nasal cavities and nasopharynx. It is here that HRV is responsible for the majority of common 
colds. Notably, infection of the upper respiratory tract epithelium by HRV is known to occur only  
in localized, punctate sections (16); infection of the epithelium does not lead to widespread tissue 
necrosis. Thus, it has been suggested that cytokine dysregulation and virus-induced inflammation 
are responsible for the majority of symptoms experienced during an HRV infection (17). Indeed, 
HRV pathogenesis is strongly associated with production of a variety of cytokines and 
chemokines, many of which are hallmarks of inflammation. The levels of IFN-γ, CXCL8, CCL2, 
CCL4, CCL5, and CCL20 found in patient sputum correlate strongly with symptom score, 
further reinforcing the role that cytokines play in HRV pathogenesis (18). Cytokines induced by 
HRV infection include  MCP1/CCL2 (17,19), RANTES/CCL5 (20), IL8/CXCL8 (21,22), IP10 
(23,24), CXCL8 , eotaxin-1/CCL11 (18), and CXCL10 (22). The majority of these cytokines 
play a role in recruiting innate immune cells such as macrophages and neutrophils to the site of 
infection. To this end, Lewis et al. found that CXCL8 levels directly correlated with the number 
of neutrophils found in sputum taken from HRV-infected individuals (18). Once recruited along 
concentration gradients of chemoattractant cyokines and chemokines, the responding innate 
immune cells then elaborate the inflammatory response, producing much of the pathology 
associated with HRV infection in the process. Among the most important cytokine responses to 
HRV is the interferon response, which is strongly associated with HRV pathogenesis. In 
otherwise healthy individuals, production of type I and type III interferon follow HRV infection 
within 24 hours (25).
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HRV infections may vary in terms of their pathology depending upon which of the 
100-plus HRV types is responsible for a given infection, although patterns of virulence amongst 
viruses belonging to the HRVA, HRB, and HRVC species remain unclear. It has been proposed 
that HRVC infections may be more pathogenic than comparable HRVA or HRVB infections, 
particularly among pediatric patient populations, based upon the finding that HRVC infections 
are overrepresented relative to the other two species in studies of children with pneumonia, 
wheezing disease, and asthma exacerbations (26-30). Consistent with these observations, a 
single-nucleotide polymorphism, rs6967330, was shown to both increase expression of the 
HRVC CDHR3 receptor and increase risk of asthma and wheezing disease in pediatric patients 
(31,32). The rs6967330 mutation also increased binding of HRVC and HRVC replication in cells 
expressing the mutant CDHR3 receptor (32). However, McColloch et al. demonstrated that HRV 
A and B infections were potentially more severe than those caused by HRVC in an adult 
population, although the results were not statistically significant after adjusting for patient sex 
(33). Jin et al. demonstrated that HRVC infections produced fewer hospitalizations than did 
HRVA or HRVB in a pediatric patient population, and further demonstrated that there was no 
disease severity discrepancy among HRVA, HRVB, and HRVC infections. In contrast, Cox et al. 
found that HRVC infections in young children were particularly associated with development of 
asthma and respiratory hospitalization (34). Taken together, these studies suggest HRVC may be 
particularly virulent in certain pediatric patients and contributes substantially to HRV morbidity 
in adult populations.
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Rhinovirus Pathology in Asthma
Although HRV-induced cold symptoms such as sore throat, nasal congestion, rhinorrhea, 
sneezing, and malaise are commonly thought of as a mere annoyance, HRV infections can be life 
threatening in individuals with otherwise compromised respiratory systems, such as those who 
suffer from COPD (35) or asthma (36). HRV infections have been estimated to cost over $40 
billion annually in the United States alone, resulting in expensive doctor’s visits, missed days of 
school and work, and lost productivity (37). A 1995 study showed that HRV infections were 
active in 80 percent of 9- to 11-year-olds presenting with asthma exacerbations during 
emergency room visits (38). In 2003, another study found similar results in adults (39). In total, it 
has been estimated that up to 80% of severe asthma exacerbations resulting in hospitalization are 
associated with HRV infections (36), and virus-induced exacerbations are responsible for both 
the majority of the health costs and the majority of the deaths associated with asthma (40). 
Although these studies are only correlational, they provide strong evidence for the role of HRV 
in asthma.
The relationship between HRV infection and asthma is complex, and HRV has been 
implicated in both predisposing individuals to developing asthma as well as exacerbating 
existing asthma symptoms. Along with respiratory syncytial virus and influenza, HRV is among 
the infectious agents that are known to predispose the immune system towards atopy (a 
predisposition towards developing allergic hypersensitivity reactions) and asthma when these 
infections occur in infancy. In children who are at a high-risk of developing asthma based on 
family history, an episode of wheezing illness caused by HRV early in life is a highly robust 
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predictor of subsequent asthma development; whereas respiratory syncytial virus infection in the 
first 6 months of life produces an odds ratio of asthma at 6 years old of 2.6, the odds ratio for 
HRV infection is 9.8 (41). Perhaps surprisingly, HRV-induced wheezing illness is a more robust 
predictor of future asthma than is aeroallergen sensitization, even in pediatric patients with a 
family history of atopy (41). Whereas the connection between early HRV infection and later 
development of asthma is clear, this linkage is associative and does not demonstrate causality. 
Indeed, it is unclear whether early HRV infection causes asthma to develop in otherwise 
high-risk individuals, or if instead children who will go on to have asthma are at higher risk for 
HRV infection due to increased susceptibility (42). In this case, early HRV infection simply 
reveals those children who are already predisposed to asthma development. As noted by Jackson 
et al., these two ideas are not mutually exclusive, and it is entirely possible that children at 
highest risk for asthma development are more likely to become infected with HRV, which in turn 
produces an inflammatory microenvironment in the airway conducive to development of asthma 
(41).
Although the exact role HRV plays in predisposing individuals to developing asthma is 
unclear, it is well understood that HRV is associated with exacerbations of asthma in both 
children (34,38,43,44) and adults (45). Indeed, in excess of 80 percent of asthma exacerbations 
are associated with upper respiratory viral infections, of which HRV is responsible for more than 
60 percent (25). In one study conducted on an adult patient population, 80% of asthma 
exacerbations were associated with symptomatic colds, and 89% of colds in asthmatics produced 
symptoms consistent with exacerbation (45). However, it has remained controversial whether 
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HRV accomplishes this exacerbation as a consequence of replicating in the lower respiratory 
tract or whether exacerbation reflects more indirect influences, such as cytokine production in 
the upper respiratory tract resulting from active replication there (25). It has also been argued 
that HRV contributes to asthma exacerbation in part by predisposing infected individuals to 
secondary infections, such as bacterial causes of pneumonia (46). Despite such arguments, HRV 
clearly does directly generate an inflammatory mileu conducive to enhanced asthma 
symptomaticity. Notably, asthmatics are known to experience longer lasting and more severe 
HRV infections than are non-asthmatics (47). It has also been suggested that the inflammatory 
recruitment of innate immune cells concomitant with HRV infection is responsible for asthma 
exacerbation. Consistent with this idea, a study of naturally acquired colds found that individuals 
who experienced asthma exacerbations demonstrated greater neutrophilia than did asthmatics 
who experienced uncomplicated HRV-driven colds (48).
Although the exact mechanisms of HRV replication that lead to asthma exacerbations 
are not fully understood, deficient type I interferon responses (49-53) and type III interferon 
responses (54), as well as deficient IL-15 production (55), have been implicated in contributing 
to more virulent HRV infection (47) and subsequent asthma exacerbation. The finding that 
interferon production is deficient in asthmatics infected with HRV is controversial (25,56), 
however, when supplied exogenously, type I and type III interferons have been shown to reduce 
replication of HRV in human bronchial epithelial cells from healthy donors (57). Notably, even 
in asthmatics, the signaling pathways involved in the interferon response are largely intact (58); 
this finding has led to the suggestion that exogenous interferon may be a useful therapeutic in 
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atopic asthmatic patients suffering from HRV-induced asthma exacerbation. IL-15 has been 
found to be deficient at baseline in asthmatics, which seems to allow HRV to replicate to higher 
titer upon experimental challenge (55). IL-15 is inducible by type I interferon and plays an 
important role in chemotaxis and immune activation; loss of IL-15 production in asthmatics 
whose production of type I interferon is deficient may potentiate the airway microenvironment 
for more robust HRV replication and enhanced viral pathology (59). Notably, the amount of 
IL-15 found in bronchoalveolar lavage fluid was found to inversely correlate with both HRV titer 
and airway hyper-responsiveness in asthmatic patients experimentally infected with HRV (55). In 
studies demonstrating a deficient interferon response associated with HRV-induced asthma 
exacerbation, HRV replication is generally found to be more prolific (59). However, 
experimental infection of asthmatics and non-asthmatics with HRV demonstrates that viral loads 
are similar in these two patient groups, which suggests that deficient IFN responses must lead to 
increased viral titer in only a small subset of patients, or that this finding is artifactual (60). 
Subsequent studies have largely failed to recapitulate these results, instead implicating the ability 
of HRV infection to synergize with ongoing atopic responses as the relevant mechanism in 
asthma exacerbation (25). Stress, smoke exposure, nitric oxide exposure, allergen exposure, 
sulfur dioxide exposure, and vitamin D deficiency have all been implicated as contributing 
factors that may synergize with HRV infection in producing asthma exacerbations (61). It has 
also been suggested that HRV infection of the lower airway biases the immune response towards 
a Th2-like phenotype, thereby enhancing atopic and asthmatic symptoms (62). The molecular 
means by which HRV infection could synergize with atopic responses is not well understood. 
Taken together, because HRV infection is neither necessary nor sufficient to produce asthma 
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exacerbation in children or adults, much more research is necessary to work out just how HRV 
contributes to asthma exacerbation. Additional longitudinal and prospective population-based 
studies are required to definitely identify the mechanism responsible for the exacerbation of 
asthma by HRV infection.
The asthma exacerbations produced by HRV infection are characterized by a number of 
physiological changes, including airway inflammation, airway obstruction and remodeling, and 
enhancement of airway hyperresponsiveness, each of which is a hallmark of clinical asthma (63). 
The term “inflammation,” when applied to the airway of a person with HRV, describes the 
process of recruiting immune cells to the lung, with the aim of mounting a more effective 
immune response (64). In order to bring immune cells to the lung, the inflammatory response 
induces vasodilation, which heightens blood flow and increases the number of immune cells 
available to enter the airway (65). For these immune cells to enter the airway from the blood, it is 
necessary to increase vascular permeability, or the “leakiness” of the endothelial barrier between 
the bloodstream and the interior of the lung (64). The inflammatory response increases vascular 
permeability by activating endothelial cells and altering their cytoskeletal structure, causing them 
to contract (65). Over time, chronic airway inflammation gives way to airway remodeling, which 
is defined as an increase in airway wall thickness, airway fibrosis, and airway vascularity (66). 
The airway hyperresponsiveness that HRV infection induces is marked by a sensitivity to 
agonists of bronchoconstriction and bronchospasm. In other words, hyperresponsiveness 
increases the susceptibility of the airway to tightening, leading to wheezing and coughing. If left 
untreated, the combination of these HRV-induced symptoms may become life threatening.
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HRV Host and Tissue Tropism
As alluded to previously, whereas the ability of HRV to produce common cold 
symptoms and to exacerbate airway conditions is fairly well characterized at the macroscopic 
level of airway inflammation and remodeling, the molecular basis for the induction of 
inflammation by HRV is poorly understood, particularly within the microenvironment of the 
lower airway that is the most relevant for asthma exacerbation. Indeed, whether HRV is even 
capable of replicating within the lower airway has been a highly controversial topic within the 
field, with many researchers historically arguing that the tropism of HRV is restricted to the 
upper airway (67).
In order to understand the controversy surrounding the tropism of HRV, it is first 
necessary to understand the concept of a virus tropism more broadly. Generally speaking, 
tropism refers to the particular type(s) of cell(s) a given virus will infect. Tropism is often 
understood at the species, tissue, and cellular levels. A given virus might infect human cells but 
not mouse cells; this virus would be said to have a human tropism. Another virus might infect 
cells in the central nervous system, but not in the alimentary canal; such a virus would be said to 
have a central nervous system tissue tropism. A third virus might infect macrophages, but not 
infect dendritic cells; such a virus would be said to have a macrophage cellular tropism.
The factors that control the tropism of human rhinovirus remain poorly understood. At 
the species level, HRV has a human tropism, although the virus has also been shown to replicate 
in other higher primates (68,69). In part, this restricted species tropism is based on HRV receptor 
utilization; for example, the majority of HRV serotypes are unable to infect mouse cells, as 
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receptors expressed on mouse cells are too dissimilar from their human homologs (70). However, 
mouse cells do not support HRV replication without extensive adaptation, even when the viruses 
are able to gain entry to the host cell (71).
At the tissue level, the basis for HRV tropism is less certain and more controversial. 
Although the epithelial cells located in the upper respiratory tract are extremely similar in 
phenotype to the epithelial cells located along the lower respiratory tract, HRV preferentially 
infects cells of the upper respiratory tract and ocular epithelia (72). Researchers have noted that 
the preferential infection of the upper respiratory tract may be a function of the fact that the 
epithelial cells of the upper respiratory tract are located nearer to HRV entry sites, such as the 
nose, eyes, and mouth (67). Many researchers had also thought that HRV replication was 
restricted to the turbinate baffles and nasopharynx of the upper airway because of the lower 
temperature present there. Whereas normal body temperature is approximately 37 degrees 
Celsius, the temperature of the upper airway is much closer to ambient temperature because of 
the constant exposure to inhaled air. The relatively high temperatures found in the lower 
respiratory tract have been experimentally determined to be less conducive to the rhinoviral 
replication cycle and subsequent rounds of infection than are the lower temperatures of the upper 
airway (73). However, other studies indicate that HRV is also capable of filtering into the lower 
airway, where the virus is endocytosed by lung epithelial cells that mobilize an immune response 
to the virus via pro-inflammatory signal transduction cascades (74). Further evidence for HRV 
replication in the lower airway came from in situ hybridization studies that revealed production 
of active rhinovirus RNA in the tissue of the lung (74). Though such in situ hybridization studies 
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demonstrate that HRV is able to complete the early steps in its life cycle, namely receptor 
attachment, host cell entry, uncoating, and RNA replication, these studies do not demonstrate that 
HRV is able to complete the later stages of its life cycle in the lower respiratory, namely 
production of viral protein, encapsulation of novel positive-sense viral RNAs, host cell lysis, and 
initiation of a second round of infection. The extent to which HRV produces multiple rounds of 
infection in the lower airway is not definitively known.
For many viruses, expression of the antiviral cytokines known as interferons and 
subsequent expression of interferon-stimulated genes (ISGs) plays a major role in controlling 
tissue tropism. For example, the tissue tropism of the closely related enterovirus poliovirus is 
largely controlled by type I interferon expression; in one study, mice who were genetically 
engineered to express the human poliovirus receptor had their expression of a panoply of ISG 
disabled, which rendered a variety of tissues besides the usual neuronal tissue able to support 
poliovirus replication (75). Notably, increasing evidence points to a defective IFN response in 
atopic patients that may contribute to HRV-induced asthma pathogenesis (49,54,76,77). 
However, within the context of the upper airway and in cell culture conditions, HRV is relatively 
resistant to the presence of IFN (78).
Collectively, ISGs are widely believed to play a central role in determining the cellular 
and tissue tropism of many viruses, leading to abortive rather than productive viral infection in a 
variety of contexts within the host. ISGs are capable of inhibiting viral replication at many points 
in the viral replication cycle, including receptor binding, entry, uncoating, genome replication, 
transcription, protein synthesis, capsid assembly, virion maturation, and budding/lysis (79). Of 
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the upwards of 1,000 human and murine ISG that have thus far been identified in the 
“interferome,” relatively few have been shown mechanistically to directly mediate antiviral 
responses (80). Of those that are well known, for example, the ISG protein kinase R (PKR) is 
activated by dsRNA to phosphorylate eIF2α, thereby halting translation of viral and host RNAs 
(81). PKR sensing of dsRNA has also been implicated in pro-apoptotic signaling and in 
mediating the IFN response to picornaviruses, including the IFN response to HRV in epithelial 
cells (82). A second well-studied ISG is oligoadenylate synthase (OAS); OAS produces 2’-5’ 
oligoadenylates, which proceed to activate RNase L and degrade both host and viral RNAs 
(83,84). Notably, constitutive expression of OAS has been shown to confer resistance to 
picornaviral infection (85). A third well-studied ISG is myxoma resistance protein (Mx). Mx is 
thought to interfere with construction of viral capsids and block trafficking of viral proteins 
within the cell (86). A fourth well-studied ISG is ISG56. ISG56 attenuates viral replication by 
sequestering eIF3 and preventing translation of both viral and host proteins (87). The specific 
activities of many other ISGs in the context of specific viral infections have yet to be carefully 
explored. Moreover, individual ISGs are highly pleiotropic, and there is great potential for 
redundancy among the various ISGs (88). Most ISG production is triggered by unknown specific 
interactions between host and viral proteins, and these interactions can vary dramatically 
between different cell types and in different cellular microenvironments. The extent to which a 
given ISG has antiviral effects that are broadly acting or virus-specific also remains unclear. 
Therefore, it is quite difficult to map antiviral effects to specific ISGs in anything close to a 1:1 
fashion. Clearly, much more work needs to be done in order to understand how ISGs 
successfully induce a protective “antiviral state” in cells that have sensed a viral threat.
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Because ISGs are plentiful, pleiotropic, and often redundant in function (Figure 3), 
viruses have had to evolve a number of mechanisms to evade their effects in order to replicate 
successfully within cells. Indeed, viruses are known to antagonize the IFN pathway at multiple 
stages, from viral recognition and production of IFN, to IFN sensing, to downstream signaling, to 
individual ISG functions (79). It is generally understood that ISG expression provides a constant 
selective pressure on viruses, forcing them to replicate quickly and to sequester any potential 
agonists of the IFN response from surveillance by pattern recognition receptors, lest the viruses 
fail to produce antagonists of the IFN-ISG system before the antiviral state freezes their 
replication (89). Therefore, the efficiency with which a virus replicates and overcomes the 
antiviral IFN response may play a major role in determining a given virus’s host range and tissue 
tropism (90).
To further elucidate the role played by ISGs in antagonizing a variety of viral infections, 
Schoggins et al. performed a flow cytometry-based overexpression screen to characterize roles 
for nearly 400 ISGs (91,92). This study identified a variety of ISGs, including RIG-I, MDA5, 
and IRF1, that had broad activities and inhibited replication of many disparate viruses, including 
hepatitis C virus, yellow fever virus, chikungunya virus, and human immunodeficiency virus. 
Notably, many ISGs were found to share a broadly acting mechanism of translation inhibition. 
However, Schoggins et al. also identified ISGs with virus-specific inhibitory effects as well as 
ISGs whose overexpression actually enhanced viral replication: In collaboration with the 
Racaniello laboratory, Schoggins et al. identified 19 genes whose overexpression significantly 
attenuated replication of fluorescently labeled PV in HeLa cells, and 9 genes that enhanced 
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poliovirus replication (Figure 4). Notably, this assay was only able to detect ISGs that would 
affect poliovirus replication at the receptor binding, entry, uncoating, protein synthesis, and 
genome replication stages; the fluorescence assay used was not able to score ISGs affecting late 
stages of the replication cycle, such as genome packaging, capsid assembly, and release of newly 
produced virions. However, it is unknown whether these ISGs exert PV-specific effects or effects 
that would also apply to other picornaviruses such as HRV.
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Figure 3. Inhibition of viral replication by interferon-stimulated genes. The ISGs produced 
as part of the interferon response are pleiotropic, redundant, and varied in function. ISGs are 
capable of inhibiting viral replication at almost every  stage of the replication cycle, including (a) 
receptor expression, (b) viral entry, (c) transcription and genome synthesis, (d) viral packaging, 
and (e) viral exit. The extent to which any  one of these steps is targeted in the ISG response to 
HRV is poorly understood. Figure adapted from McFadden et al. (2009)
Four of the ISGs identified in 
the Schoggins/Racaniello screen were 
further investigated for effects on HRV 
replication in the present study: EPSTI1 
and TDRD7 suppressed poliovirus 
replication, whereas ISG20 and EPAS1 
enhanced PV replication (Figure 4). The 
function of the EPSTI1 gene is poorly 
annotated; however, it was selected for 
further study because it is strongly 
upregulated in epithelial cells infected 
with HRV16 (93) and therefore may be 
involved in suppression of rhinoviral 
replication. The TDRD7 gene encodes a 
protein associated with cytoplasmic 
mRNA granules (94). These granules are 
sites where translationally silenced 
mRNAs and mRNAs targeted for 
degradation collect within the cell, 
usually when the cell is under stress, 
such as viral infection. Notably, enteroviruses frequently disrupt the formation of these mRNA 
granules, through the protease activity of the enteroviral 3C protein (95). TDRD7 may therefore 
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Figure 4. Dot  plot of replication of GFP-labeled 
poliovirus in the presence of overexpressed 
ISGs at  24 hours post  infection. Replication is 
normalized to an overexpressed firefly  luciferase 
control. Individual genes with their respective Z 
scores in this assay  are displayed on the right. 
Inhibitory  ISGs are displayed with a salmon-colored 
background, whereas ISGs that enhanced 
replication are displated with a mint green-colored 
background. Genes specifically  studied in the 
context of HRV replication as part of the present 
study  are highlighted in dark green. Figure is 
courtesy  of Vincent Racaniello, based on 
preliminary data.
play a role in controlling the fate of viral RNA strands within infected cells, perhaps by 
antagonizing the ability of 3C to disrupt granule formation. ISG20 is an antiviral exoribonuclease 
that acts on single-stranded RNA (96). RNA viruses including hepatitis C virus (HCV), hepatitis 
A virus (HAV) and yellow fever virus (YFV) are inhibited by ISG20 in an 
exonuclease-dependent manner (97). The exoribonuclease activity of ISG20 may be required to 
prevent HRV positive or negative strands from accumulating excessively in the cell. EPAS1 
codes for an oxygen-responsive transcription factor with nucleic acid binding motifs; the protein 
produced by the EPAS1 binds and stabilizes RNA (98). The role of EPAS1 in HRV replication is 
unclear, but it may serve to stabilize positive- or negative-sense viral RNA.
HRV Cellular Tropism - Susceptibility
Although extracellular factors such as the presence of interferon dominate at the level of 
tissue tropism, localized cell-intrinsic factors predominate at the level of cellular tropism. The 
cellular tropism of a virus is in large part controlled by whether or not a specific host cell type 
expresses the receptor that allows the virus to gain entry to the cell (99). Cells that express a 
receptor compatible with a particular virus are said to be susceptible to that virus, whereas cells 
that lack a compatible receptor are said not to be susceptible.
HRV exists as a constellation of closely genetically related but evolutionarily distinct 
serotypes, in excess of 100; these serotypes are usually phylogenetically divided into three 
groups, HRVA, HRB, and HRVC, based on genetic sequence comparison (100). The genetic 
definition of HRV species and types allows for viruses to be genotyped directly from clinical 
isolates, which reduces the time required for identifying a given HRV sample. Previously, 
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identifying a virus’s serotype required extensive cell culture and immunological assays, which 
were time consuming and labor intensive (101). Prior to their genomics-based classification, 
HRV serotypes were defined based on antigenic properties and immunologic assays, according to 
their ability to bind with specific antibodies raised against specific HRV strains (102,103). Each 
serotype, numbered sequentially starting from 1, was considered its own species. These species 
were placed in the genus Rhinovirus. However, the HRV numbering system based on HRV 
serum antibody reactivity faced a number of issues, not least of which was significant 
cross-reactivity among anti-HRV antibodies (104). Today, there are 74 HRV serotypes belonging 
to species A, 25 HRV serotypes belonging to species B, and at least 11 serotypes belonging to the 
newly described species C (104,105). These species, A, B, and C, are placed in the genus 
enterovirus (105). Of note, the genotypic comparisons that determine whether a particular isolate 
of HRV is assigned a unique type rely predominantly on genetic differences in the P1 region of 
the HRV genome, meaning that the differences controlling type divisions are largely structural in 
nature (101). Because structural differences are not the major contributor to HRV pathology, 
infection severity does not broadly correlate with virus type (33). An exception to this idea may 
be HRVC, for which more severe pathology has been reported relative to HRVA and HRVB 
species, particularly among pediatric populations (29,30). However, not all studies support the 
idea that HRVC causes more severe disease; McColloch et al. demonstrated that HRV A and B 
infections were potentially more severe than those caused by HRVC in an adult population, 
although the results were not statistically significant after adjusting for patient sex (33).
Notably, despite their extreme genetic similarity, various HRV serotypes do not all bind 
the same host cell receptor (39). Thus, HRV can also be subdivided into groups based on which 
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cellular receptor a particular HRV serotype will bind and use to gain entry into a host cell. 
Human rhinoviruses belonging to the major group, such as the HRV serotypes 16 and 39, bind 
the intercellular adhesion molecule-1 (ICAM-1) receptor (106), whereas human rhinoviruses 
belonging to the minor group, such as the HRV serotypes 1A and 2, bind the low-density 
lipoprotein receptor (LDLR) (107). In total, approximately 90 serotypes of HRV belong to the 
major group (65 serotypes of species A and 25 serotypes of species B), while relatively few 
belong to the minor group (9 serotypes of species A) (104). Despite the difference in receptor 
tropism, these viruses are closely genetically related. All four of the virus serotypes studied here 
(16, 39, 1A, 2) belong to the HRVA clade (100), and they share approximately 85% amino acid 
identity (105,108). Viruses belonging to the HRVC clade were unknown for many years as these 
viruses do not grow in standard HeLa or WisL cell cultures (109). However, molecular 
techniques such as PCR and next-generation sequencing allowed for HRVC to be identified as a 
novel HRV clade based on samples derived from clinical isolates. Approximately one third of 
HRV infections are now known to be caused by HRVC (110). Unlike major- and minor-group 
viruses, HRVC viruses utilize the human cadherin-related family member 3 (CDHR3) surface 
molecule to gain entry to host cells (32). This receptor is expressed in human lung tissue, 
bronchial epithelial cells, and in fully differentiated mucociliary epithelial cells (31,111,112). 
The ICAM-1 protein, also known by its immunological designation CD54, is a human 
cell-surface protein and a member of the immunoglobulin superfamily, the superfamily of 
proteins that includes antibodies and T-cell receptors. Its natural ligand is lymphocyte 
function-associated antigen 1 (LFA-1), and its normal functions include a wide range of 
immunological activities. The ICAM-1 protein is broadly expressed in a variety of cell types. 
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ICAM-1 is a transmembrane protein possessing an amino-terminus extracellular domain, a single 
transmembrane domain, and a carboxy-terminus cytoplasmic domain. The structure of ICAM-1 
is characterized by heavy glycosylation, and the protein’s extracellular domain is composed of 
multiple loops created by disulfide bridges within the protein’s polypeptide structure (113).
The LDL receptor is a member of a larger LDLR-related family of cell-surface 
receptors, all of which are endocytic receptors, responsible for uptake of extracellular materials. 
The LDL receptor normally functions in the cellular uptake of cholesterol. The expression of 
LDLR is tightly regulated, and LDLR is quickly upregulated or downregulated in response to 
fluctuating levels of intracellular cholesterol (114). Of relevance to the present study, infection 
with minor-group HRV correlates with upregulation of LDLR (115).
Notably, the receptor binding and host cell entry processes differ significantly between 
the major-group and minor-group viruses. Whereas ICAM-1-tropic viruses bind this receptor 
with the canyon present within their icosahedral capsids around their five-fold axes of symmetry 
(113), LDLR binds minor-group HRV very near to the viral capsid’s five-fold axis of symmetry, 
around the convergence created by multiple VP1 capsid subunits (116). The interaction between 
ICAM-1 and major-group HRV catalyzes the conformational change leading to viral RNA 
uncoating, delivering the RNA directly to the cytoplasm at the outer cell membrane (117). This 
direct mechanism of uncoating is unlike the mechanism used by minor-group viruses, which 
depend on endocytosis and acidification of late endosomes to uncoat and release their RNA 
payloads into the cell (118).
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HRV Cellular Tropism — Permissiveness
Notably, many more cells expressing receptor for a virus exist than do cells that fully 
support replication of that virus (99). Aside from the issue of susceptibility, the cellular tropism 
of a virus is largely influenced by cell-intrinsic factors internal to the cell; for a virus to have a 
tropism for a given cell type, that cell type must be both susceptible to infection and permissive 
for viral replication. When conditions within a cell allow a virus to replicate, the cell is said to be 
permissive for that virus. In contrast, cells that cannot support replication of a given virus are 
said to be non-permissive. The classical test to determine whether a cell type is permissive for a 
given virus is to transfect the cell with an infectious clone of the viral genome; cells that are 
permissive will release viable progeny viruses, whereas cells that are non-permissive will fail to 
do so. This classical test is not always a viable experimental strategy in cells that prove difficult 
to transfect, however.
The internal, cell-intrinsic factors that determine whether a cell is permissive for viral 
replication can be divided into two types: host factors required by the virus in order to complete 
its replication cycle, and host factors that inhibit viral replication when they are present within 
the cell. For a cell to be permissive, it must express the factors required by the virus, and express 
few inhibitory factors (or else the virus must be able to antagonize these factors via its own gene 
products). Of course, expression of these factors can vary according to differentiation and 
activation state of a given cell type, and it has been proposed that activation state and cell cycle 
stage play a major role in permissiveness (119). 
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In the case of HRV, the specific cell-intrinsic factors required for viral replication — and 
how these factors might vary between cell types — are poorly understood. It has been suggested 
that the picornaviral IRES contributes strongly to permissiveness differences between cell types; 
evidence pointing to the importance of the IRES comes from mutational studies of poliovirus, in 
which alterations to the IRES sequence led to concomitant alterations in cellular host range 
(120). It has also been proposed that changes in IRES sequence and structure have a proximal 
effect on translation efficiency, which itself is responsible for differential success of viral 
replication in various host cell types (121). Notably, it remains difficult to fully deconvolute the 
effects that alterations to IRES sequence have on translational efficiency and RNA replication, as 
these sequences are highly pleiotropic in function within the infected cell (122). Besides 
differences relating to the IRES and translational efficiency, most of the cellular components 
known to be required by HRV (ribosomes, vesicular trafficking machinery, etc.) are presumed to 
be common to most human cell types. However, HRV replication is observed in relatively few 
types of cells. Airway epithelial cells are where HRV replicates the most readily, as demonstrated 
by in situ hybridization studies in excised tissue samples and in samples from experimentally 
infected volunteers (67,123-125). However, HRV replication has also been observed in airway 
fibroblasts and smooth muscle cells (126); the biological significance of this replication, which 
has been observed predominantly in vitro, is not well understood. Aside from epithelial cells and 
other airway cells that may be exposed to virus by inflammation-mediated tissue remodeling, 
such as the fibroblasts and smooth muscle cells, the cells most frequently encountered by HRV 
virions are airway macrophages. The permissiveness of these cells to HRV replication is 
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controversial; they are the subject of the next section and are a major focus of the work described 
here.
Macrophages and HRV
Aside from epithelial cells, the most abundant cells in the airway are macrophages 
(127), which are the cells of the innate immune system responsible for patrolling this vulnerable 
entry route in the host (128). Though the epithelial lining itself contributes significantly to 
airway immunity, macrophages play a vital role in initiating and regulating the extracellular 
signaling that takes place between immune cells and other cells in their environment. The 
extracellular signaling capacity of macrophages is largely a product of the macrophages’ ability 
to synthesize and release pro- and anti-inflammatory signaling molecules called cytokines. In 
releasing cytokines, macrophages play an essential role in mediating immunity by relaying 
signals that recruit, activate, and induce the differentiation of immune cells such as other 
macrophages, neutrophils, natural killer cells, and T-cells. For example, alveolar macrophages 
are the predominant source of interferon-alpha during pulmonary infections with RNA viruses 
(129,130). In the context of asthma, airway macrophages play a significant role in inducing 
inflammation, and, over time, airway remodeling.
When exposed to HRV, macrophages mount a robust inflammatory response. Previous 
studies in macrophages have linked HRV receptor-mediated signal transduction to a number of 
biological endpoints associated with inflammation, including activation of 
inflammation-associated transcription factors such as NF-κB (131) and ATF-2 (19), release of 
inflammatory cytokines including MCP1/CCL2 (17,19), RANTES/CCL5 (20), IL8 (21), and 
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IP10 (23), and the dampening of the macrophage immune response to bacteria (132,133). 
Although the signaling pathways leading to these biological endpoints have yet to be fully 
elucidated, previous work suggests a signal transduction cascade involving activation of the 
small GTPase Rac (20) and downstream mitogen-activated protein kinase (MAPK) activation 
(17,19).
Notably, this signaling is at least partially receptor-mediated; neutral red- and 
UV-inactivated virus particles are still able to produce an inflammatory response in 
macrophages, albeit an attenuated one (17,23,134). As well, macrophages are known to possess 
receptors for both major- and minor-group HRV (16,17,135). However, the attenuation of the 
inflammatory response that occurs when macrophages are stimulated with replication-defective, 
UV-inactivated viruses suggests that an alternative, viral replication cycle dependent pathway is 
also important in the inflammatory response.
The exact product(s) of the viral replication cycle that serve as pathogen-associated 
molecular patterns within infected macrophages are not very well understood; however, evidence 
suggests involvement of multiple pattern recognition receptors. Viral dsRNA, which is produced 
as the single-stranded (+)-sense HRV genome replicates, is the major HRV pathogen associated 
molecular pattern (PAMP) that is sensed by host pattern recognition receptors (PRRs). PRRs that 
can recognize dsRNA (136), including RIG-I (137), MDA-5 (58,138), PKR (82), and TLR3 
(20,138,139) have all been implicated in the rhinoviral inflammatory response. Studies 
demonstrate that HRV cleaves components of the RIG-I and MDA-5 signaling pathways as part 
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of its replication cycle. Indeed, RIG-I itself is cleaved during enteroviral infections (140), and the 
downstream adapter molecule MAVS/IPS-1 is cleaved during infection with HRV (141). Based 
on studies showing that poliovirus and HRV 2A protease confer interferon resistance on 
otherwise interferon-sensitive picornaviruses such as EMCV, it has been suggested that 2Apro 
contains the essential pattern recognition receptor pathway antagonism functionality possessed 
by HRV (78). Notably, HRV has also been shown to attenuate PRR signaling at the most 
downstream portions of the PRR signaling cascade, blocking dimerization of the transcription 
factor IRF3 (50).
Although HRV antagonizes PRR signaling and is generally resistant to IFN, sensing of 
HRV by PRRs still triggers an inflammatory signaling cascade mediated by TRIF and 
MAVS/IPS-1, eventually leaving to activation of the transcription factors NF-κB, AP-1, IRF3, 
and IRF7 (17,131,142), and to the production of Type I IFNs, particularly IFN-α and IFN-β 
(76,129,143). Production of Type III IFN, or IFNλ, in response to HRV has also been reported 
(76). Following IFN autocrine and paracrine signaling, Type I and Type III IFNs induce a 
signaling cascade dependent on the JAK/STAT molecules and IRF9 that leads to formation of the 
ISGF3 complex and translocation of this transcription factor to the nucleus, where it binds to 
interferon stimulated response elements (ISRE) upstream from ISGs to induce an as of yet poorly 
characterized antiviral state and cell autonomous immunity (79,129,144,145).
Usually, for a virus to be sensed in a given cell type, it is necessary for viral replication 
to occur, and yet, despite clear roles for HRV and alveolar macrophages in asthma pathogenesis, 
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the evidence for HRV replication in macrophages that is present in the literature is sparse, 
equivocal, and unconvincing. This is similar to the state of the literature for other respiratory 
viruses, such as respiratory syncytial virus and influenza virus; in the case of both of these 
viruses, replication is abortive, and release of mature virions is either totally absent or severely 
limited (146,147).
In the case of HRV, research on whether the virus possess a tropism for 
monocyte-lineage cells dates back over two decades. In 1996, Gern et al. demonstrated that 
HRV16 entered but did not replicate in blood monocytes or alveolar macrophages (134). In their 
study, HRV titer increased 100-fold when applied to permissive HeLa cells but decreased over 
time when equivalent viral titers were applied to macrophages or monocytes, leading to no 
cytopathic effects or loss of viability in either cell population. Although radiolabeling studies 
confirmed that HRV16 virions were associated with macrophages, assays of radiolabeled uridine 
incorporation in actinomycin D-treated cells determined that HRV viral RNA replication 
occurred in HeLa cell controls but not in macrophages. Monocyte-lineage cells that were 
exposed to HRV did not suffer a loss in viability. However, HRV exposed macrophages did 
demonstrate an activated phenotype, as indicated by production of tumor necrosis factor-α 
(TNFα). Gern et al. concluded that macrophages are not permissive host cells for HRV 
replication, but suggested that these cells are active participants in anti-HRV immunity and 
elaboration of HRV-induced airway inflammation. These findings were reinforced in a 2005 
study by Hall et al., which demonstrated that infectious HRV16 could be detected in alveolar and 
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blood macrophages 1 hour after exposure, but decreasing levels were recovered over the 
following 12 hours, and no virus was detected after 24 hours (17).
In a 2006 follow-up study, Laza-Stanca et al. demonstrated that HRV replication is 
productive in the THP-1 monocyte-origin cell line, leading to release of infectious virus into 
supernatants, but is very limited in monocyte-derived macrophages. In differentiated THP-1 
cells, intracellular HRV16 RNA concentrations escalated from 2 hours to 8 hours post-infection 
and declined over the rest of a time course ending at 72 hours. HRV 3ABC and 3C proteins were 
detected in infected cells by western blot, with protein concentrations detectable at 8 hours and 
peaking at 24 hours. Protein expression of 3C was maintained through 48 hours. The viral titer 
present in supernatant escalated from 4 hours to a peak at 24 hours and declined through the 
remaining 48 hours of the time course. In an infectious center assay, 5.66 ± 0.63 percent of 
THP-1 monocyte-derived macrophages were productively infected. No such viral replication was 
observed in primary monocyte-derived macrophages; in these cells, intracellular HRV16 RNA 
levels stagnated over a 72-hour time course, declining slightly through 24 hours before escalating 
slightly through 72 hours. For primary monocyte-lineage cells, virus titers in supernatants 
declined steadily throughout a 72 hour time course, suggesting decay of input virus. Low levels 
of HRV16 3C protease protein were detected in primary monocyte-lineage cells by confocal 
fluorescence microscopy, indicating that some level of abortive replication was taking place. In 
an infectious center assay, HRV16-infected primary monocyte-derived macrophages were only 
negligibly infectious (0.1 ± 0.1 percent). Notably, in neither cell type were cytopathic effects 
observed. As argued by the authors, the difference in replicative success observed between 
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primary monocyte-derived macrophages and THP-1 derived macrophages was likely due to Type 
I IFN production, which was robust in monocyte-derived but deficient in THP-1-derived 
macrophages 24 hours after HRV infection. Intriguingly, both the permissive THP-1 cells and the 
non-permissive primary macrophages were competent producers of TNFα. Notably, when 
HRV16 was UV-inactivated, production of TNFα was strongly attenuated, suggesting that 
abortive replication was taking place in both THP-1-derived and primary monocyte-derived 
macrophages. Consistent with these findings, work by Korpi-Steiner et al. demonstrated that 
macrophages robustly release the ISG IP-10 in a response to HRV that is partially dependent on 
viral replication as well as subsequent IFN-α release and IFNAR and STAT1 activation (23).
Although the studies by Gern et al. and Laza-stanca et al. suggested that macrophages 
are not generally permissive for HRV replication, these studies were narrow in scope and 
suffered from a number of technical limitations. In particular, these studies were restricted to 
investigating replication of major-group HRV, and only investigated the replication of a single 
major-group serotype, HRV16. These studies also failed to provide any satisfactory explanatory 
mechanism for why HRV failed to replicate in these susceptible cells. Although Laza-Stanca et 
al. suggest that defective interferon production in HRV-infected THP-1 cells might explain why 
these cells are partially permissive for HRV replication, the evidence offered to support this 
claim is purely associative; no tests were conducted to determine whether interferon would block 
HRV replication in THP-1 cells.
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Study Aims
The present study was based on the hypothesis that HRV replication will vary based on 
the monocytic-lineage cell types investigated and based on the strain of HRV used (major- versus 
minor-group) due to cell-intrinsic and virus-intrinsic factors that control HRV cellular tropism. 
Furthermore, it was hypothesized that altering these cell-intrinsic and virus-intrinsic factors 
would allow experimental recapitulation of the replication profiles of different cell types and/or 
virus strains. In other words, it was hypothesized that (A) downregulating required host factors 
would suppress viral replication in permissive cells and that (B) upregulating required host 
factors would allow viral replication in otherwise nonpermissive cells. In order to modulate these 
virus- and cell-intrinsic factors, however, it first would be necessary to identify and characterize 
them. 
The present study has sought to identify HRV permissive and non-permissive monocyte 
lineage cells and to understand the mechanism(s) by which alveolar macrophages are susceptible 
but not permissive to HRV replication, whereas immortalized THP-1 monocyte-derived 
macrophages are both susceptible and permissive. The present study also sought to determine 
whether it is major- or minor-group viruses that are more capable of replicating in those 
macrophages that are permissive and to determine which differences between major- and 
minor-group HRV are relevant to the differential replicative success of these viruses in human 
monocyte-lineage cells. Completing these mechanistic studies of HRV cellular tropism in 
monocyte-lineage cells allows for the identification of novel regulators of HRV replication, 
regulators which might prove to be useful pharmacological targets in the prevention and 
treatment of common cold infections and HRV-induced asthma exacerbations. These studies are 
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also intended to shed light on which HRV pathogen-associated molecular patterns are available 
to provoke a pro-inflammatory signaling response within macrophages that do not support viral 
replication.
To accomplish these goals, it was first necessary to confirm and extend the results of 
Laza-Stanca et al (131). In contrast to this 2006 study, the studies presented here make use of 
multiple serotypes of HRV, including two serotypes each from the major- and minor-groups, 
respectively. The present study also makes use of exogenous interferon and overexpression of 
ISGs known to be inhibitory to enteroviruses to determine whether IFN signaling plays a role in 
restricting replication of HRV within monocyte-lineage cells. Furthermore, the results of the 
2006 study were extended to investigate other monocytic cell lines in addition to the primary 
cells and THP-1 monocytes previously investigated, including U937 cells and SC cells. Once 
these initial studies was accomplished, a next-generation RNA sequencing approach was used to 
determine host gene expression and viral RNA abundance within HRV infected 
monocyte-lineage cells at various time points. As described below in the Results and Discussion 
sections, various other follow-up studies were also performed as these studies were carried out. 
Taken together, these studies sought to identify the molecular determinants of HRV cellular 
tropism in monocyte-lineage cells.
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Chapter 2 – Methods
Cell Line Culture Conditions
THP-1 cells (ATCC), U937 cells (ATCC), and SC cells (ATCC) were cultured in RPMI 
1640 medium (Gibco) supplemented with 10% fetal calf serum (Gibco) and 1% penicillin / 
streptomycin (Gibco). HeLa cells (ATCC) were maintained in DMEM (Gibco) supplemented 
with 10% bovine serum (Gibco) and 1% penicillin / streptomycin (Gibco). Except where 
indicated elsewhere, cells were maintained at 37 degrees Celsius. For maturation to 
macrophages, cells were treated with 200 µM PMA (Sigma) 24 hours prior to experimentation.
Peripheral Blood Mononuclear Cell Collection and Culture
Peripheral blood mononuclear cells were obtained from healthy, college-aged (18-22) 
adult volunteers via phlebotomy (Figure 5). The protocol used for collecting blood samples was 
approved by the Lawrence University Institutional Review Board (Appleton, WI). Human blood 
samples were collected from male and female college students after the students had provided 
informed consent to the blood collection procedure. Whole blood in volumes up to 120 mL was 
collected through a venous catheter into two 60-mL sterile syringes containing the anticoagulant 
EDTA at a final concentration of 1 mM. The whole blood samples were transferred to a sterile 
glass bottle and were diluted 1:2 with HBSS (CellGro). The concentration of EDTA was brought 
to 2 mM. The diluted blood was transferred to six sterile 50-mL conical tubes containing 10 mL 
of Lymphocyte Separation Medium (CellGro) using a sterile serological pipettor. Blood cells 
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were separated using a density gradient by centrifugation at 2,000 RPM for 30 minutes at room 
temperature, without brake, using a Beckman TJ-6 centrifuge and a TH-4 rotor. Leukocytes were 
collected from the buffy coat interface between the plasma and erythrocyte layers using a 3.5-mL 
sterile disposable Pasteur pipet. The collected leukocytes were transferred to a fresh sterile 
50-mL conical tube and were brought to a volume of 50 mL with sterile HBSS. The leukocytes 
were then centrifuged for 10 minutes at 1,700 RPM. The HBSS was removed with an aspirator 
and the cell pellet was resuspended in 2 mL of ACK Lysing Buffer  (CellGro). The resuspension 
was incubated for 2 minutes to lyse any remaining erythrocytes. The lysing buffer was 
inactivated with 45 mL of HBSS and the cell suspension was centrifuged for 10 minutes at 1,200 
RPM. The HBSS was removed with an aspirator and the cells were resuspended in  macrophage 
serum-free medium supplemented with 10 ng/mL GM-CSF (PeproTech) containing 1% 
penicillin and streptomycin, RPMI 1640 supplemented with 10% fetal bovine serum and 1% 
penicillin and streptomycin, or RPMI 1640 supplemented with 10% human serum and 1% 
penicillin and streptomycin. Cells were plated to 12-well tissue culture plates at 1 mL/well. After 
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Figure 5. Isolation and purification/maturation of human blood monocyte-lineage cells. 
(A) Whole blood from male and female college students who report being in normal health is 
collected through a venus catheter into a 60-mL syringe. (B) The whole blood is separated by 
centrifugation. (C) Monocytes are collected from the “buffy coat” peripheral blood mononuclear 
cell (PBMC) layer, introduced to human or bovine serum or serum-free medium, and allowed to 
adhere to a plastic tissue culture plate, where they  mature for approximately  14 days. 
Non-adherent cells are removed by washing.
24 hours, medium was removed, adherent cells were washed once in HBSS, and fresh medium 
was supplied. From 10 to 14 days were allowed to elapse for the monocytes to differentiate. 
Differentiation was ensured through flow cytometric analysis for the presence of cluster of 
differentiation 14 (CD14), a cell surface molecule expressed on macrophages. The analysis was 
conducted with a BD FACSCaliber analytical flow cytometer and CellQuest software. Cell 
populations were approximately 90% CD14 positive and had a macrophage-like phenotype as 
observed by light microscopy.
Viral Stocks Preparation
Human rhinovirus serotypes 16, 39, 1A, and 2 were prepared from sequence-verified 
infectious clones pUC19-RV16, pACYC-RV39, pACYC-RV1A, and pACYC-RV2. In vitro 
transcription was performed by incubating linearized plasmid template with T7 RNA polymerase 
(Promega) and transfecting the viral RNA into confluent HeLa cell monolayers cells using 
DEAE-dextran (Sigma). HRV stocks were grown in HeLa cells and subsequently sedimented 
through a sucrose step gradient to remove exogenous protein and other contaminants. Cells were 
then cultured until cytopathic effect was apparent, subjected to three freeze-thaw cycles at -80° 
C, and centrifuged to remove cellular debris. The clarified supernatant was titrated by standard 
plaque assay. The HRV was then diluted to 10^9 infectious particles/mL and stored at -80 ℃ as 
previously described (17). RPMI 1640 enriched with bovine serum was used to prepare all 
necessary dilutions of virus serotypes before virus was applied.
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Capsid Swap Experiments
The P1 regions of the HRV16 and HRV1A genomes were swapped using gene splicing 
by overlap extension PCR (gene-SOEing) using a previously described technique (148). Briefly, 
primers were designed to amplify the P1 regions from HRV16 and HRV1A infectious clones 
pUC19-RV16 and pACYC-RV1A using the high-affinity polymerase Herculase II (Agilent). 
Primers mentioned are as described in Table 1. 
Table 1.
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To create the pHRV16_P1-1A construct, the 2.6 kb fragment named B1 containing the 
P1 region of HRV1A was amplified from pACYC-RV1A using primers B1F and B1R. An 
adapter fragment named B2 containing a BstAPI site 5’ to the P1 region and the ATG start codon 
of the P1 region was amplified from the pUC19-RV16 plasmid using primers B2F and B2R. An 
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adapter fragment B3 containing the 3’ end of the P1 region and a downstream ClaI site was 
amplified from pUC19-RV16 using primers B4F and B4R. Product B4 was prepared from 
fragments B1 and B2 in a megaprimer PCR reaction, along with primers B2F and B1R. Products 
B5 was prepared from fragments B3 and B4 in a megaprimer PCR reaction, along with primers 
B2F and B4R. Product B5 and pUC19-RV16 were cleaved with restriction endonucleases 
BstAPI and ClaI (NEB). Digested pUC19-RV16 was treated with calf intestinal phosphatase 
(NEB) and digested product B5 was gel purified and phenol-chloroform extracted prior to 
ligation into the digested, phosphatase-treated pUC19-RV16 plasmid with T4 ligase (NEB). 
Ligated plasmid was then midiprepped and infectious viruses were prepared by T7 transcription 
and transfection of HeLa cells.
To create the pHRV1A_P1-16 construct, the 2.5 kb fragment named A1 containing the 
P1 region of HRV16 was amplified from pUC19-RV16 using primers A1F and A1R. This 
fragment contained overlap with the A2 adapter fragment at the 5’ end and extended to an ApaI 
site at the 3’ end. Fragment A2 which contained an XmaI site at the 5’ end and overlap with the 
A1 fragment at the 3’ end was amplified from pACYC-RV1A using primers A2F and A2R. 
Fragment A3 was prepared by mixing products A1 and A2 and performing a megaprimer PCR 
reaction in the presence of primers A2F and A1R. Product A3 and pACYC-RV1A were cleaved 
with restriction endonucleases XmaI and ApaI (NEB). Digested pACYC-RV1A was treated with 
calf intestinal phosphatase (NEB) and digested product A3 was gel purified and 
phenol-chloroform extracted prior to ligation into the digested, phosphatase treated 
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pACYC-RV1A plasmid with T4 ligase (NEB). Ligated plasmid was then midiprepped and 
infectious viruses were prepared by T7 transcription and transfection of HeLa cells.
Receptor Flow Cytometry
Single-cell suspensions were washed in 5 mL flow cytometry staining buffer (PBS/2% 
bovine serum albumin). Cells were incubated with an appropriate combination of fluorochrome- 
labeled antibodies for 15-45 minutes, washed, and fixed in 0.5% paraformaldehyde in PBS. 
Distribution of surface receptors was determined using a FACSCalibur or LSRII flow cytometer. 
For each sample at least 50,000 events were collected. Analysis was conducted using FlowJo 
(TreeStar). Unconjugated murine antibodies for ICAM-1 and LDL-R were obtained from 
eBioScience, along with IgG isotype control. Phycoerythrin-conjugated anti-mouse secondary 
antibodies were also obtained from eBioScience.
HRV Plaque Assays
Plaque assays were performed in plaquing medium composed of DMEM supplemented 
with 2% bovine calf serum (Gibco), 40 mM MgCl2, 0.01% sodium bicarbonate, 1% 
penicillin/streptomycin, and 1% low-gelling type VII agarose (Sigma). This medium was applied 
to infected confluent layers of HeLa cells (ATCC) in six-well plates. Plaque assays were 
performed in duplicate and plaques were developed after incubation at 34 degrees Celsius for 96 
hours in 10% trichloroacetic acid (Sigma). Plaques were visualized by crystal violet staining 
(Sigma) and then enumerated.
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Infectious Center Assays
To determine the percentage of cells infected with HRV, an infectious center assay was 
performed, based on a protocol published previously (131). Cells were plated at 7.5E5 cells/well 
in 2 mL of cell culture medium to 6-well plates. To induce monocyte cell line differentiation to 
macrophages, cells were treated for 24 hr with phorbol myristate acetate (PMA) (Sigma) at a 
concentration of 200 nM. Following the differentiation, the PMA-containing medium was 
removed and replaced with an equal volume of fresh medium, and the cells were rested for an 
additional 24 hours in the presence or absence of 1000 U/mL IFN-α (PeproTech). 
Monocyte-lineage cells were infected with HRV16, HRV39, HRV1A, or HRV2 at a multiplicity 
of infection (MOI) of 1 or 10 in 100 mL PBS, and virus was adsorbed 1 hour at 37 degrees 
Celsius with shaking every 15 minutes. Following adsorption, cells were exposed to 0.25% 
Trypsin-EDTA (Gibco) and diluted to 10, 100, and 1000 cells per 100 mL. Suspended cells were 
adsorbed for 1 hr in duplicate on monolayers of HeLa cells (ATCC) prepared in 6-well tissue 
culture plates. Following this adsorption, culture medium was removed and replaced with a 
semisolid overlay of 1x DMEM (Gibco) with 1% penicillin/streptomycin and 1.9% Type VII 
Agarose (Sigma). The molten overlay was allowed to cool and plates were incubated for four 
days at 34 or 37 degrees Celsius. Following the incubation, monolayers were fixed in 10% 
trichloroacetic acid (Sigma) and stained with 0.1% crystal violet solution (Sigma). The number 
of virus-infected macrophages was quantitated by enumeration of plaques.
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Growth Curve Experiments
Monocyte-lineage cells at 1E6 cells/mL were cultured in 12-well plates and were 
infected with HRV16, HRV39, HRV1A, or HRV2 at an MOI of 1 or 10. For infections, cell 
culture media was aspirated, cells were infected and rocked for 1 hour, cells were washed three 
times in PBS, media was replaced, and cells were incubated for 0, 16, 24, 48, or 72 hours. After 
time had elapsed, media was collected and assessed for the presence of progeny virus by 
standard plaque assay. To assess intracellular virus, cells were lysed by freeze-thaw and 
subjected to standard plaque assay.
RNA-seq Sample Preparation
PBMC-derived macrophages, THP-1–derived macrophages, and HeLa cells were mock 
infected or infected with HRV16 or HRV1A at an MOI of 10 for 1 hour or 8 hours, and total 
RNA was extracted via Trizol reagent (Invitrogen). Extracted RNA was purified and cleaned 
using the Qiagen RNeasy kit according to the manufacturer’s instructions, including the optional 
DNase I digestion. RNA quality was ensured by bleach gel electrophoresis as previously 
described (149) and confirmed by Agilent Bioanalyzer 2100 analysis (data not shown). Purified 
RNA was supplied to the Columbia University Genome center, which prepared a 
ribominus-enriched cDNA library using the Illumina TruSeq Stranded Total RNA with 
Ribo-Zero Gold kit according to the manufacturer’s instructions. A total of 30 million 100 base 
pair, single-end reads were then obtained using the Illumina HiSeq platform.
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RNA-seq Gene Expression Analysis
In collaboration with Michal Mokry (University of Utrecht, The Netherlands), RNA-Seq 
reads were mapped against the reference genome (hg19 assembly) or HRV16 genome (GenBank 
Accession JN562722.1) or HRV1A genome (GenBank Accession No. FJ445111.1) using the 
BWA (150). Only uniquely placed reads were used for further analysis. Cisgenome v2.0 was 
used to calculate reads per 1000 base pairs of transcript per million reads sequenced (RPKM) 
values for all RefSeq annotated transcripts (151). To avoid transcripts with zero mapped tags 
interfering with logarithmic transformation of read counts, 0.1 read was added to each transcript. 
Raw read counts were normalized to the transcript length and sequencing depth and quantile 
normalized. RNA-sequencing data were deposited to the NCBI Sequence Read Archive database 
under accession number GSE55271. To determine relative expression of host genes, RNA-seq 
data were analyzed using CuffDiff. Genes were scored as significantly dysregulated if 
false-discovery rate corrected P-values were less than 0.05 when comparing a given sample to 
control.
Host Gene Expression qPCR Studies
Quantitative PCR assays were performed using an ABI 7500 cycler (Applied 
Biosystems) and Sybr Green Universal PCR Master Mix (Biorad). The thermal cycler was set to 
perform an initial set-up (95°, 10 min) and 40 cycles of denaturation (95°, 15 sec) followed by 
annealing/extension (60°, 1 min). The threshold cycle (Ct) was calculated using the 7500 
Sequence Detection Software (version 1.3.1) and the baseline and threshold values were 
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manually set by using the log view of the amplification plots. The threshold was placed above 
the background signal but within the lower one-third of the linear phase of the amplification plot. 
The relative abundance of host mRNAs was determined by subtracting the threshold cycle values 
for a given gene from the threshold cycle values for the housekeeping control gene beta-actin 
(∆Ct). Primers used in qPCR are as described in Table 1.
ISG Overexpression Studies
Bicistronic expression vectors (pTRIP.CMV.IVSB.iTagRFP) expressing RFP and 
interferon-stimulated genes of interest were obtained from the laboratory of Charles Rice at the 
Rockefeller University. Genes of interest included EPSTI1, EPAS1, TDRD7, and ISG20, as well 
as a control gene, firefly luciferase (FLuc). Constructs were introduced to 1E6 HeLa cells plated 
to 12-well plates via cationic lipid-mediated transfection with the SignaGen LipoJet transfection 
kit. For each transfection, 1 µg of DNA was used, with 2 µL of transfection reagent. Transfected 
HeLa cells were incubated 48 hours prior to viral infections. Transfected cells were 20-30% RFP 
positive as determined by fluorescence microscopy and flow cytometry.
SSqRT-PCR Experiments
Strand-specific quantitative reverse transcription PCR (SSqRT-PCR) was performed 
using primers as described in Table 1. Total RNA samples were reverse transcribed using 
SuperScript III (Fisher) and the DNA barcode tagged RT primers as indicated. Samples were 
then amplified using primers directed to the DNA barcode tag and a specific region of the 
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HRV16 genome using an ABI 7500 cycler (Applied Biosystems) and Sybr Green Universal PCR 
Master Mix (Biorad). The thermal cycler was set to perform an initial set-up (95°, 10 min) and 
40 cycles of denaturation (95°, 15 sec) followed by annealing/extension (60°, 1 min). The 
threshold cycle (Ct) was calculated using the 7500 Sequence Detection Software (version 1.3.1). 
Genome copy number was determined by interpolation from a standard curve. Samples for the 
standard curve were generated from oligomers of the qPCR amplicons (IDT).
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Chapter 3 – Results: Elucidation of HRV Cellular 
Tropism in Monocyte-Lineage Cells
Introduction
In order to characterize the molecular basis of cellular tropism of HRV in 
monocyte-lineage cells, it is first necessary to confirm and extend the results obtained in 
previous studies of HRV tropism in these cells (131,134). The purpose of the experiments 
described in this chapter is to establish the range of monocyte-lineage cells that support 
replication of major-group and minor-group HRV. Thus, a primary aim was to replicate the 
finding of Laza-Stanca et al. (131) that major-group HRV serotype 16 replicates with limited 
success in THP-1-derived macrophages, but fails to replicate in primary monocyte-derived 
macrophages. Once this finding was confirmed, an additional aim was to identify other 
monocyte-lineage cell lines and test their capacity to replicate HRV. To this end, U937 and SC 
monocyte-lineage cells were investigated for their susceptibility and permissiveness, in addition 
to the THP-1 cells and primary monocytes previously investigated by Laza-Stanca et al. As part 
of these studies, in order to confirm the susceptibility of the tested cells to HRV infection, THP-1 
cells, U937 cells, and SC cells were evaluated for their expression of the HRV receptors ICAM-1 
and LDLR by flow cytometry. A second aim of these studies was to follow up on the hypothesis 
proposed by Laza-Stanca et al. to explain why THP-1-derived macrophages but not primary 
macrophages supported HRV replication, namely that THP-1 cells failed to produce type I 
interferon in response to HRV exposure, whereas primary macrophages did produce type I 
interferon. A third aim was to test other possible explanations for the monocyte-lineage cellular 
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tropism of HRV, including whether temperature (34 degrees vs 37 degrees Celsius) affects 
whether or not HRV will replicate in monocyte-lineage cells, and whether the capsids of major- 
and minor-group HRV are responsible for conferring the replication phenotype of each of these 
types of HRV. The achievement of these aims supports the aims of the next chapter, which are to 
mechanistically characterize the molecular basis for HRV cellular tropism in monocyte-lineage 
cells.
Monocyte-Lineage Cells Express Receptors for Major- and Minor-Group HRV
Because it was previously known that monocyte-lineage cells only minimally support 
HRV replication if at all (131,134), it was hypothesized that monocyte-lineage cells might not be 
susceptible to HRV infection. For primary macrophages derived from peripheral blood 
mononuclear cells, expression of ICAM-1 and LDLR has been confirmed previously (17,19). To 
determine whether immortalized monocyte-lineage cells are susceptible to major- and 
minor-group HRV, flow cytometry was used to determine whether the ICAM-1 and LDLR 
receptors are expressed on the surface of these cells. Flow cytometry analysis determined that the 
THP-1-derived macrophages found by Laza-Stanca et al. to replicate major-group HRV 
expressed both the ICAM-1 and LDLR receptors at levels that would render these cells 
susceptible to infection (Figure 6A). U937 cells, a leukemic monocyte-lineage cell line with 
properties similar to THP-1 cells, also highly expressed the ICAM-1 and LDLR receptors when 
these cells were differentiated into macrophage-like cells (Figure 6B). SC cells, which are 
post-crisis monocyte-lineage cells, also highly expressed ICAM-1, however these cells 
demonstrated relatively low LDLR receptor expression (Figure 6C). When SC cells were 
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SampleName Freq. of Parent Geom. Mean:YG PE-A
THP1 PMA_LDLR.fcs 96.9 3179
THP1 PMA_ICAM1.fcs 100 96660
THP1 PMA_IgG Ctrl.fcs 0.046 545





















SampleName Freq. of Parent Geom. Mean:YG PE-A
U937 PMA_LDLR.fcs 99.9 5767
U937 PMA_ICAM1.fcs 100 65470
U937 PMA_IgG Ctrl.fcs 0.051 622
U937 PMA_Unstained.fcs 0.031 717
















SampleName Freq. of Parent Geom. Mean:YG PE-A
HeLa_LDLR.fcs 99.7 5937
HeLa_ICAM1.fcs 100 60161





Figure 6. HRV receptor flow cytometry. (A) 
THP-1-derived macrophages (B) U937-derived 
macrophages (C) Undifferentiated SC cells (D) 
SC-derived macrophages and (E) HeLa cells 
were stained with antibodies for the ICAM-1 or 
LDLR receptors as well as with IgG control 
antibodies.
differentiated into a macrophage-like phenotype, these cells substantially upregulated LDLR and 
maintained high expression of ICAM-1 (Figure 6D). HeLa cells, which are known to be 
susceptible to major- and minor-group HRV, were also assayed to provide a comparison (Figure 
6E).
Major- but not Minor-Group HRV Replicate in THP-1 and U937 Monocytes
Having established that monocyte-lineage cells express the ICAM-1 and LDLR 
receptors used by major- and minor-group HRV to gain entry into host cells, it was next 
determined whether these cells are permissive for HRV replication. These studies began by 
repeating the infectious center assay employed by Laza-Stanca et al. to determine permissiveness 
of THP-1-derived macrophages for major-group HRV replication (131) and extending these 
studies to include minor-group viruses. Major-group HRV16 replicated productively in 
approximately 6.2% of THP-1-derived macrophages when cells were exposed to a multiplicity of 
infection of 10. Little productive replication was observed at a multiplicity of infection of 1. The 
pattern of productive replication was similar for the major-group serotype HRV39. (Figure 7B). 
THP-1 monocytes supported major-group HRV16 and HRV39 replication as well, albeit at levels 
slightly higher than observed in THP-1-derived macrophages (Figure 7A). Infectious center 
assays performed in U937 monocytes and macrophages largely recapitulated the results obtained 
in THP-1 cells (Figure 7C, 7D). Growth curve experiments showed that major-group HRV 
serotypes 16 and 39 replicated with limited success in THP-1 cells and THP-1-derived 
macrophages, with relatively low levels of virus detectable in supernatants peaking at 24 hr and 











































Figure 7. Infectious center assays. (A) 
THP-1 monocytes (Mo), (B) THP-1 
macrophages (mϕ), (C) U937 monocytes, 
(D) U937 macrophages, and (E) HeLa cells 
were exposed to major-group (HRV16, 
HRV39) and minor-group (HRV1A, HRV2) 
HRV at an MOI of 1 or 10 in the presence 
or absence of 24 hr pretreatment with 1000 
U/mL IFN-α. Cells were then washed and 
plated onto confluent HeLa monolayers, 
and plaques were enumerated after 
conducting a plaque assay  as described in 
methods. Data are averaged from four 
independent experiments. 
serotypes 1A and 2 was undetectable in any of the monocyte-lineage cells assayed; however, 
minor-group viruses were able to replicate productively in HeLa cell controls (Figure 7E). 
Consistent with the findings of Gern et al. (134) and Laza-Stanca et al. (131) that primary 
monocyte-derived macrophages do not support major-group viral replication, infectious center 
assays performed in peripheral blood mononuclear cell-derived macrophages demonstrated no 
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Figure 8. Growth curve experiments. (A) THP-1 monocytes, (B) THP-1 macrophages, and 
(C) PBMC-derived macrophages were exposed to major-group (HRV16, HRV39) and 
minor-group (HRV1A, HRV2) HRV at an MOI of 10 in the presence or absence of 24 hr 
pretreatment with 1000 U/mL IFN-α. Cells were then incubated for 0, 16, 24, 48, or 72 hr and 
supernatants were collected. Viral content of supernatants was assessed by HeLa plaque assay 
as described in Methods. Data are averaged from four independent experiments.
productive replication (data not shown). Growth curve experiments revealed that primary 
macrophages exposed to HRV16 do not replicate the virus, with almost no virus detectable in 
supernatants at the time of infection, and declining levels of virus detectable throughout the rest 
of a 72 hour time course (Figure 8C).
HRV Replication is Insensitive to the Presence of Type I Interferon in 
Monocyte-Lineage Cells
Laza Stanca et al. hypothesized that THP-1 cells were able to replicate major-group 
HRV16 with limited success because these cells were defective in production of type I interferon 
in response to exposure to HRV(131). To test this hypothesis, infectious center assays and growth 
curve experiments were performed in THP-1 cells and  U937 cells pretreated with 1000 U/mL of 
IFN-α. Pretreatment with IFN-α did not prevent THP-1 monocytes (Figure 7A) or THP-1 
macrophages (Figure 7B) from replicating major-group HRV, and replication of HRV16 and 
HRV39 in these cells as assessed by infectious center assay did not appreciably differ from 
replication in cells that were not pretreated with type I interferon. Similar results were obtained 
when growth curve experiments were conducted in THP-1 monocytes (Figure 8A) or THP-1 
macrophages (Figure 8B); HRV16 and HRV39 replicated in the presence of type I interferon to 
levels similar to those observed in untreated cells, and the kinetics of replication were also 
similar between interferon pretreated cells and cells that were not pretreated with interferon. 
Minor-group HRV serotypes 1A and 2, which were unable to replicate in the absence of 
interferon, still could not replicate when cells were pretreated with IFN-α.
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HRV Replication in THP-1 Monocyte-Lineage Cells is not Temperature Sensitive
Because it had 
been suggested previously 
that HRV replicates more 
poorly at 37 degrees 
Celsius than it does at 34 
degrees Celsius, infectious 
center assays were 
performed in 
THP-1-derived 
macrophages at both 
temperatures, and the 
ability of major-group 
HRV16 and minor-group 
HRV1A to replicate at each 
temperature was compared. 
At an MOI of 10, HRV16 
replicated similarly regardless of which temperature was supplied, whereas HRV16 at an MOI of 
1 and HRV1A at either an MOI of 1 or 10 failed to replicate at either temperature (Figure 9).
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Figure 9. Temperature sensitivity infectious center assay. 
HRV16 or HRV1A at an MOI of 1 or 10 was applied to THP-1 
macrophages and incubated for 1 hour. Cells were then washed 
and plated onto confluent HeLa monolayers, cells were 
incubated at either 34 or 37 degrees Celsius. Plaques were then 
enumerated after conducting a plaque assay  as described in 
Methods. Data are averaged from four independent experiments.
Replicative Capacity of Major- and Minor-Group HRV is not Determined by Capsid 
Structure in Monocyte-Lineage Cells
To determine whether HRV cellular tropism is determined by susceptibility or 
permissiveness in monocyte-lineage cells, a capsid swap experiment was performed. HRV16 or 
HRV1A infectious clones were spliced as described in Methods such that the P1 structural 
regions encoding the viral capsids were swapped. RV16_P1-1A contains the P2 and P3 regions 
from HRV16 and the P1 region from HRV1A, resulting in an HRV16 virus with an HRV1A-like 
capsid. RV1A_P1-16 contains 
the P2 and P3 regions from 
HRV1A and the P1 region 
from HRV16, resulting in an 
HRV1A virus with an 
HRV16-like capsid. These 
viruses were applied at an 
MOI of 1 or 10 to either 
THP-1-derived macrophages 
or HeLa cells, and cells were 
incubated for one hour. 
Following incubation, cells 
were washed and plated on 
confluent HeLa monolayers. 
HRV16 with an HRV1A-like 
54
Figure 10. Capsid swap infectious center assay. HRV16 or 
HRV1A infectious clones were spliced as described in 
Methods such that the P1 structural regions encoding the viral 
capsids were swapped. RV16_P1-1A contains the P2 and P3 
regions from HRV16 and the P1 region from HRV1A, resulting 
in an HRV16 virus with an HRV1A-like capsid. RV1A_P1-16 
contains the P2 and P3 regions from HRV1A and the P1 
region from HRV16, resulting in an HRV1A virus with an 
HRV16-like capsid. These viruses were applied at an MOI of 1 
or 10 to either THP-1-derived macrophages or HeLa cells, and 
cells were incubated for one hour. Following incubation, cells 
were washed and plated on confluent HeLa monolayers. 
Plaque assays were then performed as described in Methods. 
Data are averaged from four independent experiments.
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0.00% 0.40% 5.20% 3.90% 0.10% 0.10% 0.40% 0.80% 0.00% 0.00%
0.05% 0.45% 5.10% 3.80% 0.30% 0.10% 0.55% 0.70% 0.00% 0.00%
0.20% 0.70% 6.00% 3.40% 0.30% 0.00% 0.10% 0.70% 0.00% 0.00%
0.00% 0.90% 6.40% 3.70% 0.20% 0.00% 0.00% 0.60% 0.00% 0.00%
0.10% 0.80% 6.20% 3.55% 0.25% 0.00% 0.05% 0.65% 0.00% 0.00%
2.50% 1.60% 5.55% 9.15% 1.65% 1.65% 3.05% 6.05% 0.00% 0.00%
0.90% 0.90% 8.05% 6.60% 0.00% 0.00%
1.10% 1.00% 9.90% 10.60% 0.00% 0.00%
1.30% 1.00% 11.70% 9.80% 0.00% 0.00%
1.20% 1.00% 10.80% 10.20% 0.00% 0.00%
1.40% 1.50% 6.40% 7.70% 1.10% 1.70% 0.70% 0.60% 0.00% 0.00%
1.10% 1.80% 7.50% 6.00% 0.70% 2.00% 1.10% 0.80% 0.00% 0.00%
1.25% 1.65% 6.95% 6.85% 0.90% 1.85% 0.90% 0.70% 0.00% 0.00%
1.20% 2.00% 6.20% 6.20% 1.50% 0.80% 1.70% 1.20% 0.00% 0.00%
2.00% 2.50% 6.00% 7.30% 1.50% 0.60% 1.10% 1.30% 0.00% 0.00%
1.60% 2.25% 6.10% 6.75% 1.50% 0.70% 1.40% 1.25% 0.00% 0.00%
1.50% 1.70% 6.10% 6.20% 2.00% 1.10% 1.80% 1.20% 0.00% 0.00%
2.10% 2.20% 5.00% 6.00% 2.00% 0.90% 1.20% 1.10% 0.00% 0.00%
1.80% 1.95% 5.55% 6.10% 2.00% 1.00% 1.50% 1.15% 0.00% 0.00%
4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 3.00 3.00 3.00 3.00 4.00 4.00
0.89% 0.94% 6.23% 5.78% 1.46% 1.71% 7.35% 7.48% 0.73% 0.58% 1.22% 2.47% 1.10% 0.89% 0.95% 0.78% 0.00% 0.00%
0.24% 0.11% 0.61% 0.75% 0.14% 0.27% 1.19% 0.92% 0.15% 0.18% 0.34% 0.60% 0.50% 0.44% 0.40% 0.33% 0.00% 0.00%
Average Means - IFN + 24 hr IFNα 
1000 U/mL
HRV 16 MOI 1
HRV 16 MOI 10
HRV39 MOI 1
HRV39 MOI 10
HRV 1A MOI 1
HRV 1A MOI 10












SEM - IFN + 24 hr IFNα 
1000 U/mL
HRV 16 MOI 1
HRV 16 MOI 10
HRV39 MOI 1
HRV39 MOI 10
HRV 1A MOI 1
HRV 1A MOI 10






























HRV  2 M
OI 1















+ 24 hr IFNα 1000 U/mL























































Major- and minor-group viral RNA strands 
accumulate differentially in THP-1 macrophages
Differential major/minor-group HRV 
replication is not HRV capsid/receptor dependent
Michael T. Schreiber1, Sagi Shapira1, Mikhail Mokry2, David J. Hall3, and Vincent R. Racaniello1
1Department of Microbiology & Immunology, Columbia University, New York, NY 10032
2Division of Pediatrics, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
3Department of Chemistry, Lawrence University, Appleton, WI 54911
Major-group but not minor-group human rhinoviruses replicate in cell-line derived 









Major- but ot minor-group HRV replicates in 
















Human Rhinovirus Cellular Tropism
1MS282.3 2MS282.3 3MS282.3 4MSMS282.3 5MS282.3 6MS282.3 7MS282.3 8MS282.3 9MS282.3 10MS282.3 11MS282.3 12MS282.3 13MS282.3 14MS282.3 15MS282.3 16MS282.3
HRV 16 MOI 1 HRV16 MOI 1  
+ 24 hr IFN 
1000 U/mL 
HRV16 MOI 10 HRV16 MOI 
10 + 24 hr 
IFN 1000 U/
mL 
HRV16 MOI 1 HRV16 MOI 1  





10 + 24 hr 
IFN 1000 U/
mL 
HRV39 MOI 1 HRV39 MOI 1  





10 + 24 hr 
IFN 1000 U/
mL 
HRV1A MOI 1 HRV1A MOI 1  













1.00E+03 1.00E+03 1.00E+03 1.00E+03 1.00E+03 1.00E+03 1.00E+03 1.00E+03 1.00E+03 1.00E+03 1.00E+03 1.00E+03 1.00E+03 1.00E+03 1.00E+03 1.00E+03
24 14 54 96 6 8 88 89 11 10 99 106 23 7 34 55
26 18 57 87 7 10 73 43 13 10 117 98 10 9 27 66
2.50% 1.60% 5.55% 9.15% 0.65% 0.90% 8.05% 6.60% 1.20% 1.00% 10.80% 10.20% 1.65% 0.80% 3.05% 6.05%
0.14% 0.28% 0.21% 0.64% 0.07% 0.14% 1.06% 3.25% 0.14% 0.00% 1.27% 0.57% 0.92% 0.14% 0.49% 0.78%


















HRV2 MOI 1 HRV2 MOI 1 + 
IFN
HRV2 MOI 10 HRV2 MOI 10 
+ IFN
























0.10% 0.50% 5.00% 3.70% 0.50% 0.10% 0.70% 0.60% 0.00% 0.00%
0.00% 0.40% 5.20% 3.90% 0.10% 0.10% 0.40% 0.80% 0.00% 0.00%
0.05% 0.45% 5.10% 3.80% 0.30% 0.10% 0.55% 0.70% 0.00% 0.00%
0.20% 0.70% 6.00% 3.40% 0.30% 0.00% 0.10% 0.70% 0.00% 0.00%
0.00% 0.90% 6.40% 3.70% 0.20% 0.00% 0.00% 0.60% 0.00% 0.00%
0.10% 0.80% 6.20% 3.55% 0.25% 0.00% 0.05% 0.65% 0.00% 0.00%
2.50% 1.60% 5.55% 9.15% 1.65% 1.65% 3.05% 6.05% 0.00% 0.00%
0.90% 0.90% 8.05% 6.60% 0.00% 0.00%
1.10% 1.00% 9.90% 10.60% 0.00% 0.00%
1.30% 1.00% 11.70% 9.80% 0.00% 0.00%
1.20% 1.00% 10.80% 10.20% 0.00% 0.00%
1.40% 1.50% 6.40% 7.70% 1.10% 1.70% 0.70% 0.60% 0.00% 0.00%
1.10% 1.80% 7.50% 6.00% 0.70% 2.00% 1.10% 0.80% 0.00% 0.00%
1.25% 1.65% 6.95% 6.85% 0.90% 1.85% 0.90% 0.70% 0.00% 0.00%
1.20% 2.00% 6.20% 6.20% 1.50% 0.80% 1.70% 1.20% 0.00% 0.00%
2. 0% 2.50% 6.00% 7.3 % 1.5 % 0.60% 1.10% 1.30% 0.00% 0.00%
1.60% 2.25% 6.10% 6.75% 1.50% 0.70% 1.40% 1.25% 0.00% 0.00%
1.50% 1.70% 6.10% 6.20% 2.00% 1.10% 1.80% 1.20% 0.00% 0.00%
2.10% 2.20% 5.00% 6.00% 2.00% 0.90% 1.20% 1.10% 0.00% 0.00%
1.80% 1.95 5.55% 6.10% 2.00% 1.00% 1.50% 1.15% 0.00% 0.00%
4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 3.00 3.00 3.00 3.00 4.00 4.00
0.89% 0.94% 6.23% 5.78% 1.46% 1.71% 7.35% 7.48% 0.73% 0.58% 1.22% 2.47% 1.10% 0.89% 0.95% 0.78% 0.00% 0.00%
0.24% 0.11% 0.61% 0.75% 0.14% 0.27% 1.19% 0.92% 0.15% 0.18% 0.34% 0.60% 0.50% 0.44% 0.40% 0.33% 0.00% 0.00%
Average Means - IFN + 24 hr IFN 
1000 U/mL
HRV 16 MOI 1
HRV 16 MOI 10
HRV39 MOI 1
HRV39 MOI 10
HRV 1A MOI 1
HRV 1A MOI 10












SEM - IFN + 24 hr IFN 
1000 U/mL
HRV 16 MOI 1
HRV 16 MOI 10
HRV39 MOI 1
HRV39 MOI 10
HRV 1A MOI 1
HRV 1A MOI 10















































+ 24 hr IFN 1 00 U/mL























































Major- and minor-group viral RNA strands 
accumulate differentially in THP-1 macrophages
Differential major/minor-group HRV 
























































































































































































capsid replicated similarly to wild-type HRV16 in infected THP-1 macrophages, whereas 
HRV1A with an HRV16-like capsid recapitulated the failure to replicate observed with wild-type 
HRV1A. Both capsid swapped viruses replicated successfully in HeLa cells (Figure 10).
Discussion
The results described in this chapter confirmed and extended the results obtained by 
Gern et al.(134) and Laza-Stanca et al. (131). As described by Laza-Stanca et al., whereas THP-1 
cells support limited replication of major-group HRV, primary macrophages are not a site of 
productive HRV replication (Figures 7, 8). In the experiments described here, unlike in previous 
studies, two serotypes of major-group HRV were used, namely HRV16 and HRV39. The use of 
multiple major-group serotypes and achievement of similar results with both suggests that 
major-group viruses generally perform similarly in their ability to replicate with limited success 
in leukemic monocyte-lineage cells. 
Notably, U937 cells, which like THP-1 cells are leukemic in nature, closely phenocopy 
the HRV replicative capacity of THP-1 cells (Figures 7, 8). SC cells, which are a post-crisis 
monocyte line and not leukemic in nature, phenocopy primary cells in that they fail to support 
HRV replication. This finding suggests that cancerous transformation induces gene expression 
changes that enable limited replication of major-group HRV in THP-1 cells and U937 cells; 
whether cell cycle or mitogenic genes are important for HRV replication is poorly understood, 
and this finding suggests investigating their importance may be a promising avenue of study.
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Laza-Stanca et al. proposed in their 2006 study that THP-1 cells may be partially 
permissive for major-group HRV replication because these cells do not express type I interferon 
when exposed to HRV. To test this hypothesis, type I interferon was supplied ectopically to 
THP-1 cells prior to assays of HRV replication. In both infectious center assays and growth 
curve experiments (Figures 7, 8), exogenous type I interferon failed to prevent major-group HRV 
replication and allowed replication to occur at levels similar to cells unexposed to exogenous 
interferon. Thus, the interferon hypothesis of Laza-Stanca et al. must be rejected.
In neither the experiments of Gern et al. nor those of Laza-Stanca et al. were 
minor-group HRV included or compared to major-group HRV for their ability to replicate in 
monocyte-lineage cells. Previous studies (19,20) have suggested that major- and minor-group 
HRV produce distinct signal transduction cascades upon exposure to monocyte-lineage cells, 
resulting in differential pro-inflammatory cytokine responses. Here, the replicative capacity of 
monocyte-lineage cells for major-group and minor-group HRV was directly compared, by both 
infectious center assay (Figure 7) and growth curve (Figure 8). Whereas THP-1 and U937 cells 
are partially permissive for major-group HRV16 and HRV39 replication, all of the 
monocyte-lineage cells examined in the experiments described here failed to support replication 
of two minor-group HRV serotypes (HRV1A and HRV2). The warmer temperature present in the 
lower airway was excluded as a cause of why HRV might not replicate successfully in 
monocyte-lineage cells by a temperature-sensitivity infectious center assay (Figure 9). 
Major-group HRV replicated with approximately equal efficiency at 37 degrees (lower airway 
temperature) as it did at 34 degrees (upper airway temperature), whereas minor-group HRV 
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failed to replicate at either temperature. Major- and minor-group HRV replicated with similar 
efficiency at 34 degrees Celsius and 37 degrees Celsius when infectious center assays were 
performed in HeLa cells (data not shown).
Differences between major-group and minor-group HRV that lead these viruses to have 
different replication phenotypes in THP-1 and U937 cells are not understood. Involvement of the 
capsids of these viruses in determining monocyte-lineage cellular tropism can be ruled out, 
however; the capsid-swap experiment described in Figure 10 demonstrates that major-group 
HRV16 replicates with limited success in THP-1 monocyte-lineage cells even when the P1 
region of the HRV16 genome is replaced with that of the minor-group HRV1A, thereby giving 
HRV16 an HRV1A-like capsid. Conversely, HRV1A with an HRV16-like capsid fails to 
appreciably replicate in these cells, just as the wild-type HRV1A does. Taken together, these 
results suggest that differences between major-group and minor-group viruses that exert their 
effects post-entry are responsible for the variation in cellular tropism observed between these two 
HRV groups. In other words, the capsid-swap experiments confirm that it is permissiveness and 
not susceptibility that controls HRV cellular tropism in monocyte-lineage cells.
In the next chapter, the molecular mechanisms responsible for the restricted cellular 
tropism of HRV in monocyte-lineage cells are further explored, from the perspective of both host 
and viral gene expression.
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Chapter 4 – Results: Mechanistic Exploration of HRV 
Cellular Tropism in Monocyte-Lineage Cells
Introduction
In the previous chapter, it was demonstrated that major-group HRV replicate with 
limited success in THP-1 and U937 monocyte-lineage cells, whereas minor-group HRV do not 
replicate in these cells. Neither major- nor minor-group HRV replicated in primary 
monocyte-lineage cells. It was further demonstrated that major-group HRV replication in those 
monocyte-lineage cells that were permissive was not sensitive to the presence of exogenous type 
I interferon. Additionally, all of the cell types tested were shown to be susceptible to both major- 
and minor-group HRV. Having established which cell types are susceptible and permissive for 
HRV replication, the aim of this chapter is to investigate the molecular mechanisms that control 
the HRV cellular tropism in monocyte-lineage cells. To this end, next-generation RNA 
sequencing techniques were employed to determine possible host factors that contributed to HRV 
tropism in monocyte-lineage cells. Specifically, RNA-seq was employed to determine host gene 
expression in primary monocyte-derived macrophages and THP-1-derived macrophages at 
various time points after infection with either major-group HRV16 or minor-group HRV1A. 
Genes of interest uncovered by the RNA-seq experiments were then further investigated by 
quantitative PCR. RNA-seq studies also revealed information about the accumulation of 
positive- and negative HRV viral RNA strands within the cell; this information was used to 
assess whether HRV RNA accumulated in monocyte-lineage cells and whether this accumulation 
was inappropriate. Lastly, following up on the previous studies by Schoggins et al. that indicated 
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certain interferon-stimulated genes suppressed or enhanced replication of the HRV-related 
enterovirus poliovirus (91,92), the expression of a subset of these ISGs was investigated in 
monocyte-lineage cells to determine whether they influenced HRV tropism. After establishing 
baseline expression values for these genes, namely the EPSTI1 and TDRD7 genes, which 
suppressed poliovirus replication, and ISG20 and EPAS1 genes, which enhanced poliovirus 
replication (Figure 4), these genes were over-expressed in HeLa cells. A strand-specific 
quantitative PCR-based assay was then developed and used to determine whether positive- and 
negative-strand replication was altered in the HeLa cells over-expressing the ISGs. Taken 
together, these studies addressed the central aim of the present work, which was to identify HRV 
permissive and non-permissive monocyte lineage cells and to understand the mechanism(s) by 
which primary macrophages are susceptible but not permissive to HRV replication, whereas 
immortalized THP-1 monocyte-derived macrophages are both susceptible and permissive.
Major-Group HRV16 Induces a More Robust Transcriptional Response in 
Macrophages Than Does Minor-Group HRV1A
Because major-group HRV replicate with limited success in monocyte-lineage cells, 
whereas minor-group HRV fail to replicate in monocyte-lineage cells entirely, RNA-sequencing 
studies were performed to determine gene expression differences that might explain the 
differential replicative capacity of monocyte-lineage cells for major- and minor-group HRV. 
Human peripheral blood monocyte-derived macrophages exposed to a multiplicity of infection of 
10 of the major-group HRV16 experience a much more robust dysregulation of host gene 
expression than do cells equivalently exposed to HRV1A (Figure 11). Patterns of gene expression 
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were similar between 1 hr (not shown) and 8 hr post infection, but changes were more robust at 
the latter time point.
Interferon-Stimulated Genes are Among Those Upregulated by Major-Group 
HRV16 but not Minor-Group HRV1A in Monocyte-Lineage Cells
Among those genes most dysregulated by HRV infection of primary monocyte-lineage 
cells were a series of interferon-stimulated genes (Figure 12A). APOL3, GBP1, GBP5, IFI44, 
Mx1, and Mx2 were all significantly upregulated by HRV16 at 8 hours post infection, as 
determined by CuffDiff analysis of RNA-seq data. The APOL3, GBP1, GBP5, and Mx1 genes 
were among the most significantly upregulated genes, with expression more than 5-fold higher 
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purchased from Qiagen. The thermal cycler was set to perform an
initial set-up (95u, 10 min) and 40 cycles of denaturation (95u,
15 sec) followed by annealing/extension (60u, 1 min). After
determining that all primer pairs used amplified with approxi-
mately equal efficiency (data not shown), the relative amount of
mRNA for the genes of interest was determined by subtracting the
threshold cycle (Ct) values from the Ct value for the internal
control gene b-actin (DCt). Data are depicted as fold difference
from untreated control using the 22DDCt method.
Statistical Analysis
ELISA protein concentrations were calculated by averaging the
triplicate values for each experiment and interpolating from the
standard curve, with differences between control and treatment
groups determined by paired Student’s t-test for means. All
statistical analyses were performed in SPSS (originally the
Statistical Package for the Social Sciences) (version 16.0) using a
significance cutoff of p,0.05.
Results
HRV16 and HRV1A Differentially Alter Gene Expression in
Human Macrophages
Although HRV16 and HRV1A are phylogenetically closely
related, with both belonging to clade-A, and sharing 85% amino
acid identity [4,5,39], they bind different receptors, and we have
previously demonstrated that these viruses induced different
biological outcomes in human primary macrophages [40]. To
follow up upon this observation, we used high-throughput
sequencing to identify differentially expressed genes. Human
primary macrophages derived from blood were exposed to either
HRV16 or HRV1A at an MOI of 10. Eight hours post-infection,
total RNA was isolated and sequenced on the Illumina HiSeq
platform. Substantially more genes were differentially expressed in
HRV16 exposed cells compared to those macrophages exposed to
HRV1A (Figure 1A and 1B) and a subset of those genes was
chosen for further examination (Table 1).
HRV Exposure Alters Mitochondrial Membrane Potential
The initial step of a virus binding its cognate receptor can
function in a similar manner as a ligand binding its receptor and
subsequently activating a signal transduction pathway. Few studies
have examined if the initial signal transduction induced by a virus
is important to pathogenesis. HRV provides a unique opportunity
to examine this possibility as different serotypes can bind at least
two different receptors. Interestingly, mitochondrial genes MT-
ND1 and MT-ND6 were differentially expressed between
macrophages exposed to HRV16 and HRV1A (Table 1). Mac-
rophages exposed to HRV16 and HRV1A showed more
mitochondrial activity (less fluorescence) by rhodamine 123
staining than control at 1 hour post-infection (Figure 2A).
Subsequently at 8 hours post-infection, HRV16 and control
mitochondrial membrane potential were indistinguishable; how-
ever, the membrane potential of macrophages exposed to HRV1A
remained high in accordance with the differential gene expression
of mitochondrial genes observed from RNA sequencing (Table 1).
Altered Expression of Inflammatory Cytokines Resulting
from HRV Exposure
A variety of cytokines are produced in macrophages and
epithelial cells following HRV exposure [11,13,28,41–48].
HRV16 and HRV1A treated macrophages were analyzed by
RNA sequencing which detected differential expression of several
cytokines important in the HRV and asthmatic response, namely
CCL20, CCL2, IL-10 and CXCL10. Differential cytokine
expression and production was confirmed via quantification with
both qPCR (Figure 3) and sandwich ELISA (Figure 4). As would
be expected using human primary immune cells, there was a
substantial range in responses across subjects.
CCL2 and CCL20 are prominent inflammatory cytokines that
have been identified previously as important immune response
molecules during HRV exposure in both epithelial cells [49] and
macrophages [13,40]. In particular both of these cytokines are
acutely chemotactic, recruiting lymphocytes, neutrophils, and
monocytes to the site of their release. Both CCL2 and CCL20
were significantly elevated with exposure to the major-group
HRV16 compared to minor-group HRV1A, demonstrated both
by a difference in mRNA (Figure 3A, 3B) and protein expression
(Figure 4A, 4B).
IL-10 is well known for its anti-inflammatory effects [50] and
may provide a replicative advantage to several viruses [51–54].
Interestingly, HRV1A suppressed IL-10 mRNA transcription
(Figure 3C) and protein expression (Figure 4C) whereas HRV16
increased expression compared to control (Figure 4C).
Not all inflammatory mediators were expressed differentially
after macrophages were exposed to the two serotypes of HRV.
CXCL10 is another pro-inflammatory chemokine that is released
as a result of interferon gamma (IFN-c) production and is
responsible for monocyte and macrophage recruitment as well as
some anti-cancer activities [33,46,55]. We observed no significant
differences observed in the expression of this chemokine in mRNA
(Figure 3D) or proteins (Figure 4D).
Differential MAPK Phosphorylation Induced by HRV16
and HRV1A
The MAPK p38 becomes activated as a result of stress from the
environment, such as ultraviolet radiation, heat shock, or
cytokines, and it is involved in promoting the production of
inflammatory cytokines [13]. HRV1A elicited an increase in
phospho-p38 activation within 15 minutes and continued to
increase gradually up to 60 minutes. HRV16 induced a high
amount of activation within 15 minutes that increased to a peak at
30 minutes. Activation was progressively decreased at the 60- and
90- minute time points. HRV1A caused a gradual increase in p38
Figure 1. Major- and minor-group HRV produce distinct gene
expression profiles in primary macrophages. Human peripheral
blood mononuclear cell-derived macrophages were exposed to HRV1A,
HRV16, or mock at an MOI of 10 for 8 hours. Total RNA was extracted
and ribosomal RNA was depleted and sequenced on the Illumina HiSeq
platform. Raw read counts for were normalized to the transcript length
and sequencing depth and quantile normalized. Gene expression
profiles for macrophages exposed to A) HRV1A or B) HRV16 are
presented as quantile n rmalized read counts per tran cript per k of
transcript per million sequencing tags (RPKM), log2 scale.
doi:10.1371/journal.pone.0093897.g001
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Figure 11. Major- and minor-group HRV produce distinct gene expression profiles in 
primary macrophages. Human peripheral blood mononuclear cell-derived macrophages were 
exposed to HRV1A or HRV16 at a multiplicity  of infection of 10 or exposed to mock infection for 
8 hours. As described in Methods, total RNA was extracted and sequenced. In collaboration 
with Michal Mokry, raw  read counts were normalized to the transcript length and sequencing 
depth as well as quantile normalized. Gene expression profiles for macrophages exposed to 
(A) HRV1A or (B) HRV16 are presented as quantile normalized read counts per transcript per 
kb of transcript per million sequencing tags (RPKM), log2 scale.
following HRV16 infection and 8 hours of incubation. These genes were not strongly induced at 
1 hour post infection with HRV16, and their induction was much more mild and not statistically 
significant (n = 1, see Figure 12 legend for description of CuffDiff analysis) when cells were 
exposed to HRV1A and incubated for 8 hours. When RNA-seq studies were performed in THP-1 
monocyte-derived macrophages, the patterns of gene expression observed in primary 
macrophages did not hold. APOL3, GBP1, GBP5, IFI44, Mx1, and Mx2 were not expressed at 
levels significantly different from mock-infected cells when THP-1-derived macrophages were 




















































































































Figure 12. RNA-Seq gene expression data. (A) PBMC-derived macrophages or (B) 
THP-1-derived macrophages were infected with HRV16, HRV1A, or mock conditions and 
incubated for 1 or 8 hours. Following incubation, RNA was extracted and sequenced as 
described in Methods. Using the CuffDiff software package, relative expression of the 
functionally  APOL3, GBP1, GBP5, IFI44, Mx1, and Mx2 genes was computed. Genes were 
selected based on significant differential expression in the PBMC-derived macrophage dataset 
for the HRV16 8 h.p.i time point (α-reject = 0.05). Data are expressed as fold-change from 
mock-infected cells and are representative of one experiment.
Following these RNA-seq studies, confirmatory quantitative reverse-transcription PCR 
(qRT-PCR) was performed to assess expression of the dysregulated genes identified in a wider 
subset of monocyte-lineage cells. Experiments were performed in THP-1-derived macrophages 
(Figure 13A), SC-derived macrophages (Figure 13B), and peripheral blood monocyte-derived 
macrophages (Figure 13C). Expression data obtained by RT-qPCR did not broadly agree with the 
data obtained by RNA-seq. Whereas the GBP1 and APOL3 genes were consistently found to be 
upregulated at 8 hours post infection with HRV16 in PBMC-derived macrophages, other genes 
found to be upregulated in RNA-seq were only found to be modestly dysregulated by qRT-PCR. 
In THP-1-derived macrophages, qRT-PCR identified an upregulation of GBP5 following HRV16 
infection that was not observed by RNA-seq. Notably, qRT-PCR did detect a strong upregulation 
of IFN-α2 in THP-1-derived macrophages in response to HRV16 infection that was not observed 
via RNA-seq. No reads of IFN-α2 were contained in the RNA-seq dataset (data not shown). SC 
cells, whose gene expression was not assayed by RNA-seq, demonstrated few significant gene 
expression changes when exposed to HRV16 and HRV1A. In these cells, GBP1 and GBP5 were 
slightly upregulated following HRV16 exposure, and IFN-α2 was also induced. Preliminary 
overexpression studies performed in HeLa cells with the genes identified here showed no 

































































































































































Figure 13. Confirmatory qRT-PCR. (A) THP-1-derived macrophages, (B) SC-derived 
macrophages, and (C) peripheral blood mononuclear cell-derived macrophages were exposed 
to mock infection or HRV16 or HRV1A at a multiplicity  of infection of 10 and incubated for 1 or 8 
hours prior to harvesting of RNA and qRT-PCR assay performed as described in Methods. Data 
are expressed as fold change from mock infected control ± SEM and are averaged from four 
independent experiments.
Positive- and Negative-Strand HRV Viral RNA are Produced in Both Permissive 
and Nonpermissive Monocyte-Lineage Cells
In order to determine whether HRV genomes replicate successfully in monocyte-lineage 
cells, in collaboration with Michal Mokry, RNA-seq sequence reads mapping to positive- and 
negative-sense HRV viral RNA were quantitated following exposure of peripheral blood 
mononuclear cell-derived macrophages to HRV16, HRV1A, or mock infection and incubation 
for 1 or 8 hours (Figure 14). Both major-group HRV16 and minor-group HRV1A viral RNA 
positive- and negative-strands were detected at 1 and 8 hours. At 1 hour post infection, the 
HRV16 positive-to-negative strand ratio was 887:1. The ratio at 1 hour for HRV1A was 156:1. At 
8 hours post infection, these ratios declined to 156:1 and 97:1, respectively, while the overall 
amount of viral RNA increased.
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Figure 14. HRV viral RNA strand ratios in peripheral blood mononuclear cell-derived 
macrophages as determined by RNA-seq. Cells were exposed to mock infection or HRV16 or 
HRV1A at an MOI of 10 and incubated for 1 or 8 hours before RNA was harvested, sequenced, 
and aligned to the positive- and negative-sense HRV genome as described in Methods. Data 
analysis performed in collaboration with Michal Mokry. Data are representative of one 
experiment.
HRV16 and HRV1A Viral RNA Molecules are Produced Completely in Infected 
Macrophages
Having detected HRV16 and HRV1A viral genomes in infected macrophages, it was 
next determined whether these genomes were produced completely or instead transcribed 
abortively. Analysis of RNA-seq data performed in collaboration with Michal Mokry revealed 
that 100 base-pair reads mapping to the HRV16 and HRV1A genomes spanned the full length of 
the genome, at both 1 and 8 hours post infection (Figure 15). Hotspots with increased read counts 
were observed in both the HRV1A and HRV16 genomes; however, these hotspots were relatively 
evenly distributed across the genome, and did not suggest any physiologically relevant 
enrichment. These hotspots instead can be explained as artifacts of the RNA-seq fragmentation 




























































53 1196 2596 3992 5388 6789
Figure 15. Coverage map of HRV viral genome RNA-seq reads. Peripheral blood 
mononuclear cell-derived macrophages (A) exposed to HRV16 and incubated for 1 hour, (B) 
exposed to HRV16 and incubated for 8 hours, (C) exposed to HRV1A and incubated for 1 hour, 
and (D) exposed to HRV1A and incubated for 8 hours were harvested, RNA was extracted, and 
the RNA was sequenced. In collaboration with Michal Mokry, viral RNA reads were aligned to 
the HRV16 and HRV1A genomes. Data are representative of one experiment.
Poliovirus-Inhibitory and Poliovirus-Enhancing Interferon-Stimulated Genes Do 
Not Appreciably Alter Replication of HRV or Disrupt HRV Viral RNA Strand Ratios
In previous work performed collaboratively between the Rice and Racaniello 
laboratories(92), it was demonstrated that a number of interferon-stimulated genes significantly 
alter the replicative success of poliovirus when these genes are over-expressed (Figure 4). Based 
on the finding that negative strands of the HRV RNA genome appear to accumulate in infected 
monocyte-lineage cells (Figure 14), ISGs that both significantly altered the replicative success of 
poliovirus and had functions relevant to the persistence or degradation of RNA were selected for 
study in the HRV/monocyte-lineage cell system. Genes selected for further study included 
EPAS1, EPSTI1, ISG20, and TDRD7. The expression of these genes was evaluated in 
THP-1-derived macrophages, peripheral blood mononuclear cell-derived macrophages, and 
HeLa cells over a 24-hour time course following infection with major-group HRV16 at a 
multiplicity of infection of 10. No dysregulation of these genes was observed in infected 
THP-1-derived macrophages over the 24-hour time course (Figure 16A). In peripheral blood 
mononuclear cell-derived macrophages, no appreciable changes in expression of these genes 
were detected in cells cultured with human serum (Figure 16B); however, peripheral blood 
mononuclear cell-derived macrophages cultured in bovine serum experienced an upregulation of 
ISG20 and, to an extent, TDRD7 over the full time course, with expression of both genes 
peaking at 24 hours post infection (Figure 16B). EPAS1 and EPSTI1 were not appreciably 
dysregulated in bovine serum-cultured peripheral blood mononuclear cells exposed to HRV16 
(Figure 16B). Notably, the expression of EPAS1, EPSTI1, ISG20, and TDRD7 in HeLa cells was 
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not responsive to HRV16 infection; the expression of these genes remained close to levels 
observed in uninfected cells throughout a 24-hour time course.
Although the EPAS1, EPSTI1, ISG20, and TDRD7 genes were not dysregulated by 





































































































































Figure 16. ISG expression in cells exposed to major-group HRV16. The expression levels 
of EPAS1, EPSTI1, ISG20, and TDRD7 were assessed in (A) THP-1-derived macrophages, (B) 
peripheral blood mononuclear cell-derived macrophages, and (C) HeLa cells exposed to 
major-group HRV16 and incubated for 0, 4, 8, or 24 hours. For peripheral blood mononuclear 
cell-derived macrophages, “B” indicates the cells were cultured in fetal bovine serum, whereas 
“H” indicates the cells were cultured in human serum. Data are presented ± SEM and are 
averaged from four independent experiments.
genes would alter HRV viral 
RNA strand ratios or virus 
yields in HRV-infected cells. 
To determine whether these 
genes would alter viral RNA 
strand ratios or RNA yields, a 
strand-specific quantitative 
reverse transcription PCR 
(SSqRT-PCR) assay was 
developed (described in 
Methods) that would 
distinguish positive- and 
negative-sense HRV viral 
RNAs from each other. A spike-and-recovery validation experiment (Figure 17) determined that 
the developed SSqRT-PCR assay was indeed strand specific and established a sensitivity range of 
10^1 to 10^8 viral genome copies, even in the presence of as many as 10^6 copies of the 
opposing strand. Having validated this SSqRT-PCR assay, the assay was employed in an 
overexpression experiment featuring the four previously identified interferon-stimulated genes. 
EPAS1, EPSTI1, ISG20, and TDRD7 were overexpressed in HeLa cells as described in Methods 
and overexpressing cells were infected with major-group HRV16 at a multiplicity of infection of 
10 in a 24-hour time course. SSqRT-PCR was then performed on RNA samples derived from the 
infected cells. Notably, neither accumulation of positive strands (Figure 18A) nor accumulation 
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(-) Strand + 1E6 Copies (+) Strand R^2 = 0.91
(+) Strand + 1E6 Copies (-) Strand R^2 = 0.93
Figure 17. Spike-and-recovery validation of SSqRT-PCR 
experiment. SSqRT-PCR was performed using primers 
specific to either positive- or negative-strand HRV16 and a 
serial dilution of plasmids containing the HRV16 amplicon. To 
validate the specificity  of the assay, 1E6 copies of the 
opposite strand were added to each sample prior to 
amplification. Data are representative of three technical 
replicates and are displayed ± standard error. Based on this 
validation, the dynamic range of the assay was determined to 
be 1E1 to 1E8 genome copies per sample.
of negative strands (Figure 18B) was affected by overexpression of these interferon-stimulated 
genes at any point during the 24-hour time course.
Discussion
The aim of this chapter was to elucidate the molecular mechanisms controlling HRV 
cellular tropism within monocyte-lineage cells. To this end, a next-generation RNA-sequencing 
approach was used to identify host genes dysregulated by major- and minor-group HRV infection 
in monocyte-lineage cells while also characterizing the accumulation of major- and minor-group 
HRV viral RNA within these infected cells.
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Figure 18. Major-group HRV16 replication in cells overexpressing select  ISGs. Select 
ISGs were overexpressed in HeLa cells as described in Methods, and cells were infected with 
HRV16 at an MOI of 10 and incubated for 0, 4, 8, or 24 hours. A strand-specific quantitative 
reverse transcription PCR assay  was then used to detect (A) positive-sense HRV16 viral RNA 
and (B) negative-sense HRV16 viral RNA. Data are averaged from four independent 
experiments. “FLuc” is the firefly luciferase gene, here serving as a control.
These RNA-seq studies revealed that major-group HRV16 induces a more robust host 
gene response than does minor-group HRV1A (Figure 11). Of those genes differentially 
regulated in HRV16-infected cells, many of the most strongly upregulated genes had annotations 
as interferon-stimulated genes (Figure 12). Interestingly, whereas APOL3, GBP1, GBP5, IFI44, 
Mx1, and Mx2 were upregulated in major-group HRV16-infected peripheral blood mononuclear 
cell-derived macrophages at 8 hours post infection, these genes were not strongly induced by 
minor-group HRV1A infection. These genes were also not noticeably dysregulated in 
THP-1-derived macrophages infected with either HRV16 or HRV1A. Taken together, these 
results suggest that major-group and minor-group HRV provoke distinct patterns of gene 
expression within monocyte-lineage cells, and that primary macrophages respond to HRV 
infection in a manner that is materially very different from that observed in leukemic cell 
line-derived macrophages. This finding is consistent with earlier work (19,20) demonstrating 
distinct pro-inflammatory signaling profiles that occur in macrophages responding to either 
major-group or minor-group HRV exposure. 
The RNA-sequencing studies performed here, by dint of their ability to detect positive- 
and negative-strand viral RNAs in infected cells, also revealed that THP-1- and PBMC-derived 
macrophages exhibit a late block in the HRV replication cycle prior to the release of mature 
virions from the cell; this late block results in accumulation of positive- and negative-sense HRV 
genomic RNA strands over the course of an 8-hour infection (Figure 14). Notably, 
negative-sense strands of both the HRV16 and HRV1A genomic RNA persist late into infection 
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and increase in abundance relative to positive-sense RNA. Taken together with the knowledge 
that primary macrophages are not permissive for HRV replication, the accumulation of 
negative-sense RNA may suggest a molecular mechanism for the finding that no viable progeny 
viruses are recovered from infected primary macrophages. To test this hypothetical mechanism, 
studies were performed to determine whether positive and negative-sense strands of the HRV 
genome were produced at full length or merely abortively, which could be caused by such 
mechanisms as RNA polymerase-ribosome collision. Based on the mapping of RNA-seq viral 
RNA reads to the HRV genome (Figure 15), replication of positive- and negative-sense HRV 
RNA was complete, and did not occur abortively.
Further exploration of why HRV negative-sense RNA might accumulate in infected 
monocyte-lineage cells was performed by looking to the subset of interferon-stimulated genes 
known to either inhibit or enhance the replication of the closely related virus poliovirus (Figure 
4) and selecting for further study those genes that could play a role in controlling 
positive-to-negative strand ratio in infected cells. As described in the Introduction, these genes 
were EPSTI1 and TDRD7, which suppressed poliovirus replication, and ISG20 and EPAS1, 
which enhanced poliovirus replication (Figure 4). Quantitative PCR analysis of RNA samples 
derived from HRV infected monocyte-lineage cells and HeLa cells demonstrated that these four 
genes are not strongly regulated by HRV infection (Figure 16). However, clear differences in 
expression were observed between infected primary macrophages (Figure 16B) and infected 
leukemic THP-1 cell line-derived macrophages (Figure 16A), namely that the ISG20 and 
TDRD7 genes are induced over a 24-hour time course in primary macrophages, but not induced 
73
in the cell line-derived macrophages. Notably, use of human serum rather than bovine serum in 
culturing the primary macrophages abrogated the upregulation of these genes. In unpublished 
work by the Paul Bertics laboratory (University of Wisconsin), use of a filter to remove 
immunoglobulins from human serum substantially altered the signal transduction response of 
macrophages exposed to HRV (Paul Bertics and Dave Hall, personal communication). Therefore, 
it is possible that immunoglobulins present in human serum attenuate the ISG signaling response 
in macrophages exposed to HRV.
Because THP-1 cell line-derived macrophages are partially permissive for HRV16 
replication, whereas primary macrophages are not (Figure 8), it was hypothesized that 
differential expression of one or both of these genes might contribute to the differential 
replicative success of HRV16 in these cell types. To test whether expression of these genes could 
affect the replicative success of HRV and/or alter the positive-to-negative strand ratio of viral 
RNA, a stand-specific qRT-PCR assay was developed (Figure 17) and employed to detect viral 
RNA replication in HeLa cells overexpressing the four interferon-stimulated genes indicated 
above. Notably, neither the abundance of positive-sense HRV RNA (Figure 18A) nor the 
abundance of negative-sense HRV RNA (Figure 18B) was altered in cells overexpressing any of 
the four studied interferon-stimulated genes. However, this experiment does not conclusively 
rule out involvement of these genes in HRV RNA strand replication for two reasons. Firstly, flow 
cytometric analyses detected RFP signal from the bicistronic overexpression vectors used to 
introduce the ISGs into HeLa cells in only a maximum of 30% of cells transfected (data not 
shown). The poor efficiency of the transient transfection performed here suggests that, at best, 
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overexpression of these genes could influence viral RNA replication by a factor of 30%, which 
might be neither statistically not physiologically significant, nor detectable reliably by the 
SSqRT-PCR assay used herein. Secondly, due to the refractory nature of monocyte-lineage cells 
when it comes to transient transfection, overexpression studies were performed in HeLa cells, 
rather than the more physiologically relevant THP-1- and peripheral blood mononuclear 
cell-derived macrophages. It is entirely possible that overexpressing these genes within the 
specific microenvironment of monocyte-lineage cells would have a significant effect on HRV 
viral RNA replication despite the fact that no such effect is observed in HeLa cells. 
In conclusion, there are likely virus-specific and host cell-specific factors that contribute 
to HRV cellular tropism in monocyte-lineage cells. The experiments performed herein suggest a 
late block in the major- and minor-group HRV replication cycle that occurs after HRV viral RNA 
strand replication but prior to release of mature progeny virions from infected cells. These 
experiments have also confirmed earlier findings that primary macrophages are not permissive 
for HRV replication whereas leukemic THP-1 cell line-derived macrophages are partially 
permissive, as well as findings suggesting that major- and minor-group HRV provoke different 
signaling responses in monocyte-lineage cells leading to differential expression of 
pro-inflammatory mediators such as interferon-stimulated genes.
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Chapter 5 – Discussion
Introduction
The purpose of this study was to determine the extent to which major- and minor-group 
HRV are capable of replicating in monocyte-lineage cells and to determine the mechanisms by 
which monocyte-lineage cells are rendered non-permissive for HRV replication. To this end, 
experimental tools were developed and used to determine the extent to which HRV replicate in 
primary and cell line-derived macrophages and to determine which stages of the HRV replication 
cycle could be completed in these cells.
Major-Group but not Minor-Group HRV Replicate in Leukemic Cell-Line Derived 
Macrophages, but not in Primary Macrophages Regardless of the Presence of 
Type I Interferon
Through the course of these studies, it was found that major-group, but not minor-group 
HRV are capable of limited replication in monocyte-lineage cells. Specifically, major-group HRV 
replicated with limited success in monocytes and macrophages derived from leukemic monocytic 
cell lines (THP-1, U937), but not in primary peripheral blood mononuclear cell-derived 
macrophages or in macrophages derived from the post-crisis monocytic cell line SC (Figures 7, 
8). Notably, U937 cells, which like THP-1 cells are leukemic in nature, closely phenocopy the 
HRV replicative capacity of THP-1 cells (Figures 7, 8). SC cells, which are a post-crisis 
monocyte line and not leukemic in nature, phenocopy primary cells in that they fail to support 
HRV replication. This finding suggests that cancerous transformation induces gene expression 
changes that enable limited replication of major-group HRV in THP-1 cells and U937 cells; 
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whether cell cycle or mitogenic genes are important for HRV replication is poorly understood, 
and this finding suggests investigating their importance may be a promising avenue of study.
Importantly, the findings obtained here were consistent with earlier work on HRV 
cellular tropism in monocyte-lineage cells. For example, Gern et al. demonstrated that HRV fail 
to replicate in primary monocytes and macrophages (134). In 2006, Laza-Stanca et al. also found 
that HRV failed to replicate in primary macrophages; however, Laza-Stanca et al. also examined 
whether THP-1 leukemic cell line-derived macrophages would be permissive for HRV 
replication (131). In their study, Laza-Stanca et al. found that 5.8% of HRV16-infected 
THP-1-derived macrophages would form infectious centers when plated onto HeLa monolayers. 
Although Laza-Stanca et al. infected macrophages with HRV16 at a concentration of 1 TCID50 
unit per cell, which is not directly comparable to the multiplicity of infection of 10 used herein, 
their findings agreed closely with the 6.2% of HRV16-infected THP-1-derived macrophages 
found to create infectious centers in the present study (Figure 7B).
In order to explain why HRV replicated with limited success in THP-1-derived 
macrophages but not primary macrophages, Laza-Stanca et al. proposed that THP-1 cells may be 
partially permissive for major-group HRV replication because these cells do not express type I 
interferon when exposed to HRV. To test this hypothesis, type I interferon was supplied 
ectopically to THP-1 cells prior to assays of HRV replication. In both infectious center assays 
and growth curve experiments (Figures 7, 8), exogenous type I interferon failed to prevent 
major-group HRV replication and allowed replication to occur at levels similar to cells 
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unexposed to exogenous interferon. Thus, the interferon hypothesis of Laza-Stanca et al. must be 
rejected.
It has also commonly been proposed that the elevated temperature of the lower airway, 
where alveolar macrophages naturally come into contact with HRV, presents a barrier to HRV 
replication. Temperature sensitivity infectious center assays comparing HRV replication at 37 
degrees Celsius and 34 degrees Celsius did not detect discernible differences in the ability of 
major- and minor-group HRV to replicate within THP-1-derived macrophages between these two 
temperatures. Thus, incubation temperature can be rejected as a basis for restricting the cellular 
tropism of HRV in monocyte-lineage cells.
Notably, neither Gern et al. nor Laza-Stanca et al. explored whether major-group viruses 
other than HRV16 would replicate in monocyte-lineage cells, and neither explored whether any 
minor-group HRV would replicate. In the present study, the major-group virus HRV39 was found 
to largely phenocopy HRV16, suggesting that major-group viruses replicate with similar success 
in monocyte-lineage cells (Figure 7, 8). In contrast, neither of two minor-group HRV, HRV1A 
and HRV2, were capable of replicating in monocyte-lineage cells. Taken together, these results 
suggest clear differences between major- and minor-group HRV that are capable of influencing 
HRV cellular tropism. In previous work (19,20), major- and minor-group HRV were found to 
elicit distinct pro-inflammatory signaling cascades in HRV-exposed monocyte-lineage cells, for 
example activating the small GTPase Rac with differential kinetics.
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Because major- and minor-group HRV are nearly genetically identical, with the primary 
difference between them being their use of distinct receptors, it would be reasonable to assume 
that differences in their signaling capacity and replicative success in monocyte-lineage cells 
would be attributable entirely to this differential receptor utilization. One might even predict that 
monocyte-lineage cells are simply not susceptible to minor-group HRV replication, perhaps 
because the minor-group HRV receptor LDLR is not basally expressed in macrophages. 
However, multiple lines of evidence suggest that differences between major- and minor-group 
HRV exert their effects intracellularly, and that the functional differences controlling whether 
these viruses replicate in monocyte-lineage cells have little to do with receptor utilization and 
susceptibility, and more to do with permissiveness. Firstly, flow cytometry experiments 
confirmed that both the major-group HRV receptor ICAM-1 and the minor-group HRV receptor 
LDLR are expressed on the surface of monocyte-lineage cells, including THP-1-derived 
macrophages (Figure 6A). Secondly, capsid swap experiments were performed that altered 
HRV16 to contain the P1 capsid-encoding region of HRV1A and vice versa. In these 
experiments, HRV16 with an HRV1A-like capsid largely phenocopied the replicative success of 
native HRV16 in THP-1-derived macrophages, whereas HRV1A with an HRV16-like capsid was 
equally as unable to replicate in these cells as was the native HRV1A virus (Figure 10). Notably, 
both capsid-swapped viruses were able to replicate in susceptible and permissive HeLa cells. 
Taken together, these results suggest intracellular differences between HRV16 and HRV1A 
control differences in these viruses’ cellular tropisms.
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Major- and Minor-Group HRV Produce Distinct Transcriptional Responses in 
Monocyte-Lineage Cells
Consistent with the idea that the replicative capacity of major-group and minor-group 
HRV are different in monocyte-lineage cells due to differences that exert their effects 
intracellularly, RNA-seq studies of the transcriptional profiles induced by major-group HRV16 
and minor-group HRV1A revealed that major-group HRV16 induces a more robust host gene 
response than does minor-group HRV1A (Figure 11). This more robust transcriptional response 
is commensurate with the major-group virus’s reproductive success in these cells. Of those genes 
differentially regulated in HRV16-infected cells, many of the most strongly upregulated genes 
had annotations as interferon-stimulated genes (Figure 12). Interestingly, whereas APOL3, 
GBP1, GBP5, IFI44, Mx1, and Mx2 were upregulated in major-group HRV16-infected 
peripheral blood mononuclear cell-derived macrophages at 8 hours post infection, these genes 
were not strongly induced by minor-group HRV1A infection. These genes were also not 
noticeably dysregulated in THP-1-derived macrophages infected with either HRV16 or HRV1A. 
Taken together, these results suggest that major-group and minor-group HRV provoke distinct 
patterns of gene expression within monocyte-lineage cells, and that primary macrophages 
respond to HRV infection in a manner that is materially very different from that observed in 
leukemic cell line-derived macrophages. This finding is consistent with earlier work (19,20) 
demonstrating distinct pro-inflammatory signaling profiles that occur in macrophages responding 
to either major-group or minor-group HRV exposure.
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Despite Limited Permissiveness, Infected Monocyte-Lineage Cells Produce Both 
Positive- and Negative-Sense Major- and Minor-Group HRV Viral RNA
RNA-seq studies allowed for assessment of the abundance of positive- and 
negative-strand viral RNAs in infected cells. When these RNA-seq studies were performed, 
reads from major-group HRV16 and minor-group HRV1A viral RNAs were obtained in both 
PBMC-derived and THP-1 derived macrophages at 1 and 8 hours post infection. These results 
were not anticipated, as the only one of these virus/cell combinations known to produce viable 
progeny viruses is HRV16 infection of THP-1-derived macrophages. In other words, despite the 
fact that limited to no viable progeny viruses are detected, both positive-sense and negative-sense 
viral RNA accumulates in both the nonpermissive peripheral-blood mononuclear cell-derived 
macrophages and the partially permissive THP-1-derived macrophages. Notably, the relative 
abundance of negative-strand viral RNA reads increased from 1 hour post infection to 8 hours 
post infection, for both major-group HRV16 and minor-group HRV1A (Figure 14). Taken 
together, these results suggest a block to HRV replication in monocyte-lineage cells that is late in 
the replication cycle, and that may influence the positive-to-negative strand ratio of HRV viral 
RNA. Notably, reads from the viral genome spanned its length with approximately equal 
coverage, suggesting that polymerase-ribosome collision or polymerase stalling is not a relevant 
mechanism in affecting this strand ratio (Figure 15).
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Interferon-Stimulated Genes Implicated in Controlling the Replicative Success of 
Poliovirus do not Appreciably Influence the Replicative Success of HRV
Once it had been established that HRV viral RNA accumulates in infected 
monocyte-lineage cells despite the fact that these cells support limited, largely abortive viral 
replication, it became necessary to explain why this might occur. In particular, the accumulation 
of negative-sense viral RNA suggested that dysregulation of HRV genome replication might be a 
relevant mechanism in rendering monocyte-lineage cells non-permissive for HRV. Further 
exploration of why HRV negative-sense RNA might accumulate in infected monocyte-lineage 
cells was performed by looking to the subset of interferon-stimulated genes known to either 
inhibit or enhance the replication of the closely related virus poliovirus (Figure 4) and selecting 
for further study those genes that could play a role in controlling positive-to-negative strand ratio 
in infected cells. As described in the Introduction, these genes were EPSTI1 and TDRD7, which 
suppressed poliovirus replication, and ISG20 and EPAS1, which enhanced poliovirus replication. 
Notably, these four genes were not strongly regulated by major- or minor-group HRV infection in 
either monocyte-lineage cells or HeLa cells (Figure 16). However, clear differences in expression 
were observed between infected primary macrophages (Figure 16B) and infected leukemic 
THP-1 cell line-derived macrophages (Figure 16A), namely that the ISG20 and TDRD7 genes 
are induced over a 24-hour time course in primary macrophages, but not induced in the cell 
line-derived macrophages. In primary macrophages, both ISG20 and TDRD7 were upregulated 
by HRV16 infection, with an escalating response as the time course progressed (Figure 16B). 
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Because THP-1 cell line-derived macrophages are partially permissive for HRV16 
replication, whereas primary macrophages are not (Figure 8), it was hypothesized that 
differential expression of one or both of these genes might contribute to the differential 
replicative success of HRV16 in these cell types. To test whether expression of these genes could 
affect the replicative success of HRV and/or alter the positive-to-negative strand ratio of viral 
RNA, a strand-specific qRT-PCR assay was developed and employed to detect viral RNA 
replication in HeLa cells overexpressing the four interferon-stimulated genes indicated above. To 
ensure strand specificity, genetic barcode tagging was employed during the reverse transcription 
step, allowing for a strand-specific quantitative reverse transcription qPCR (SSqRT-PCR) assay 
to be performed. This assay was used to characterize both viral replication kinetics and positive- 
and negative-strand accumulation. The assay was validated using spike-and-recovery 
experiments; in these experiments, the assay gave a linear response from approximately 10^1 to 
10^8 viral genome copies per sample for each strand, even in the presence of 10^6 copies of 
opposing strand (Figure 17). Once this assay had been validated, it was employed with RNA 
samples obtained from cells overexpressing the four interferon-stimulated genes described 
above. Such overexpression was accomplished in HeLa cells using RFP-containing bicistronic 
expression constructs from the Rice and Racaniello poliovirus ISG screen (92). TDRD7, 
EPSTI1, ISG20, and EPAS1 were expressed in  approximately 30% of transiently transfected 
cells, as determined by fluorescence microscopy and flow cytometry (data not shown).
Notably, neither the abundance of positive-sense HRV RNA (Figure 18A) nor the 
abundance of negative-sense HRV RNA (Figure 18B) was altered in cells overexpressing any of 
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the four studied interferon-stimulated genes. However, this experiment does not conclusively 
rule out involvement of these genes in HRV RNA strand replication for two reasons. Firstly, flow 
cytometric and fluorescent microscopic analyses detected RFP signal from the bicistronic 
overexpression vectors used to introduce the ISGs into HeLa cells in only a maximum of 30% of 
cells transfected (data not shown). The poor efficiency of the transient transfection performed 
here suggests that, at best, overexpression of these genes could influence viral RNA replication 
by a factor of 30%, which might be neither statistically not physiologically significant, nor 
detectable reliably by the SSqRT-PCR assay used herein. Secondly, due to the refractory nature 
of monocyte-lineage cells when it comes to transient transfection, overexpression studies were 
performed in HeLa cells, rather than the more physiologically relevant THP-1- and peripheral 
blood mononuclear cell-derived macrophages. It is entirely possible that overexpressing these 
genes within the specific microenvironment of monocyte-lineage cells would have a significant 
effect on HRV viral RNA replication despite the fact that no such effect is observed in HeLa 
cells.
Methodological Innovations, Strengths, and Limitations
The present study featured a number of methodological innovations and strengths, 
although there were also notable limitations to the methods employed. One of the most important 
strengths of the present study involved the inclusion of multiple major- and minor-group HRV 
serotypes, as opposed to the single major-group strain used in previous studies (131,134). 
Whereas previous studies were unable to make claims about major-group and minor-group 
viruses more broadly, the present study used two strains from each group, which behaved 
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similarly to each other in terms of their ability to replicate within monocyte-lineage cells. These 
studies therefore allow for claims to be made about the general properties of viruses belonging to 
the major and minor groups. A second strength was the use of modern, next-generation RNA 
sequencing techniques to globally profile host gene expression as well as positive- and 
negative-sense HRV viral RNA replication in monocyte-lineage cells. This technique captured a 
fuller picture of the environment within the infected monocyte-lineage cells than was available in 
previous studies, which examined only expression of a select few genes and which did not 
explore viral RNA accumulation. A third strength of the study was the use of multiple biological 
end points to evaluate HRV replication in monocyte-lineage cells. Infectious-center assays, 
growth curves, RNA-sequencing, and SSqRT-PCR assays provided corroborating information on 
the ability of major- and minor-group HRV to replicate in primary and cell line-derived 
monocyte-lineage cells. The multiple lines of evidence provided by these redundant assays 
therefore enhanced the strength of the conclusions that could be drawn about the replicative 
success of HRV in monocyte-lineage cells. Moreover, the SSqRT-PCR assay developed over the 
course of these studies was an innovation that may be useful in further studies of HRV 
replication.
Methodological weaknesses associated with the present study have in large part to do 
with the quality of the data returned by the RNA-sequencing studies. Cost constraints required 
that few time points be included in the analysis, which hampered the ability to capture different 
phases of host gene response and viral RNA accumulation. As well, the RNA-seq experiment 
was performed only once, and at a relatively shallow read depth (30 million reads per sample). 
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The low sequencing depth coupled with inclusion of total RNA (so as to capture viral RNA 
reads) resulted in poor coverage of the host genome. For example, no reads were obtained from 
the IFNα2 gene in the RNA-seq dataset, whereas IFNα2 was found to be induced by qRT-PCR 
analysis of infected monocyte-lineage cells (Figure 13). Performing RNA-seq studies at a greater 
read depth may have revealed additional, interesting cases of differential gene expression 
between HRV16- and HRV1A-infected cells, thereby yielding a more complete picture of the 
monocyte-lineage cell host response to HRV infection. Investigating RNA abundance at a wider 
range of time points would also have provided a fuller picture of host gene expression and HRV 
positive-to-negative strand ratios throughout the full HRV replication cycle.
A further weakness in the present study was created by the inability to successfully 
modulate gene expression in monocyte-lineage cells. These cells are highly refractory to 
transient transfection, which forced reliance on overexpression studies in HeLa cells as a model 
system. Even in these cells, it proved difficult to obtain transient transfections more efficient than 
approximately 30 percent. Unfortunately, the ISG expression constructs used in these studies are 
somewhat cytotoxic, rendering them unsuitable for stable transfection (John Schoggins, personal 
communication). As a result, with only 30% of cells transiently transfected, the largest effect size 
observable in such assays as SSqRT-PCR is also approximately 30%. Although no changes in 
virus RNA yield of that magnitude were observed, even if they had been, it would be difficult to 




Although the studies described herein have improved knowledge of the factors 
contributing to HRV cellular tropism in monocyte-lineage cells, there is much that remains to be 
understood. Whereas the accumulation of positive- and negative-sense viral RNA in infected 
monocyte-lineage cells has been implicated as a contributing factor, neither the exact mechanism 
by which HRV replication is blocked nor the exact point in the HRV replicative cycle where 
blockage occurs has been definitively identified. Similarly, although it has been shown that 
significant differences between major- and minor-group HRV exert their effects post-entry to 
create differential transcriptional responses as well as differential replicative capacity in 
monocyte-lineage cells, it remains unclear exactly which differences between major- and 
minor-group viruses are responsible for these differential effects. Finally, whereas a number of 
interferon-stimulated genes were evaluated for their ability to influence HRV replication, it 
remains unclear which interferon-stimulated genes, if any, are important for restricting 
replication of HRV in monocyte-lineage cells. Future work will pinpoint the exact step in the 
HRV replication cycle where blockade occurs in monocyte-lineage cells and elucidate the 
molecular mechanisms that contribute to this blockade.
As hypothesized herein, it is possible that monocyte-lineage cells lack some essential 
host factor that is required for steps in the HRV replication cycle. Alternatively, it is possible that 
monocyte-lineage cells express some factor that prevents these steps from being carried out. 
Based on the results obtained from the RNA-seq analysis, it would seem that these inhibited 
steps must be downstream from RNA synthesis, at such crucial points as genome packaging, 
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virion maturation, and release of mature virions. Thus, future work will involve additional assays 
to determine whether potentially relevant monocyte-lineage cell gene products are involved in 
controlling abortive replication of HRV. Whereas many of the studies modulating gene 
expression described herein were performed in HeLa cells due to technical limitations, future 
work may take advantage of lentivirus-mediated transfection strategies to directly modulate gene 
expression in monocyte-lineage cells. The CRISPR-Cas9 system, which has rapidly gained 
currency in the scientific community for its ability to disrupt expression of narrowly targeted 
genes, would allow for precise ablation of specific genes within monocyte-lineage cells. Initial 
candidates for such ablation might include the differentially expressed genes identified in the 
RNA-seq and qPCR studies described herein, as well as the full set of interferon-stimulated 
genes described as significantly affecting the replicative success of poliovirus (Figure 4). 
Additional genes might be identified by more extensive RNA-seq studies, with a wider selection 
of time points and a higher read depth, which would allow for a more accurate and complete 
description of genes that are dysregulated upon infection of monocyte-lineage cells with HRV.
Additionally, the idea that viral RNA accumulation itself directly contributes to the 
limited replicative success of HRV in monocyte-lineage cells suggests follow-up experiments 
that could shed light on how this accumulation is deleterious to the replicating virus. One 
hypothesis that had been considered was that positive- or negative-sense RNAs are not produced 
as full transcripts in monocyte-lineage cells, rendering the accumulating RNA nonfunctional. 
Such abortive RNA replication might be caused, for example, by collision of ribosomes with 
RNA polymerase on nascent RNA strands. Although evidence from the RNA-seq data suggests 
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that no regions of the HRV genome are enriched in terms of their representation within the 
infected cell (Figure 15), it is still possible that extreme ends less than the 100 bp reading 
window of the RNA-seq experiment in length could be clipped from the HRV genome during the 
course of positive- and/or negative-sense RNA synthesis. To test this hypothesis, future work 
might include a 5’ rapid amplification of cDNA ends PCR (RACE-PCR) experiment, seeking to 
demonstrate that ends of the HRV genome are intact within infected macrophages. Such 
deletions have previously been found to be a relevant mechanism contributing to virus tropism in 
Coxsackie virus replication, and RACE-PCR was employed successfully to study these deletions 
(152,153).
A second hypothesis that might explain how HRV viral RNA accumulation could lead to 
non-permissiveness is that HRV RNA molecules fail to properly localize within infected 
macrophages. Thus, future work might include experiments to visualize the localization of HRV 
RNA within infected monocyte-lineage cells. Such experiments might include development of 
fluorophore-binding, RNA aptamer-labeled HRV constructs for live imaging of HRV RNA strand 
accumulation via flow cytometry and fluorescence microscopy. Inserting a fluorescent RNA 
aptamer tag in the 3’ UTR in forward and reverse orientation would allow for the monitoring of 
positive- and negative-sense viral RNA strand accumulation within the infected cell. Such 
fluorophore-binding tags have been used successfully for RNA imaging in mammalian cells 
(154). According to Bert Semler, who has studied picornaviral requirements for intact 3’ UTR 
sequences extensively, HRV should remain viable with an RNA aptamer knocked into the 3’ 
UTR (personal communication). Should RNA aptamer-based techniques prove not to be viable, 
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probe-based fluorescence in situ hybridization studies could be used to localize positive- and 
negative-sense viral RNA within the cell. Such approaches have successfully localized positive- 
and negative-sense enteroviral RNA at the tissue level previously (155).
If HRV replication is not inhibited by the accumulation of positive- and/or 
negative-sense RNA within the cell, but is instead inhibited at some later step in the replication 
cycle, other experiments may be able to determine exactly where this blockade occurs. For 
example, Western blotting for various HRV proteins could reveal defects in HRV protein 
synthesis, co-translational proteolytic processing, or in maturation of HRV virions. Electron 
microscopy might also reveal whether HRV virions or empty capsids accumulate within infected 
cells, and whether the vesicular structures HRV uses as replication factories display their usual 
morphology in monocyte-lineage cells. Of note, lysis of infected macrophages by repeated 
freeze-thaw does not reveal any additional infectious particles as determined by plaque assay 
(data not shown).
Other follow-up experiments might choose to further characterize the unique properties 
of leukemic monocyte-lineage cells and major-group HRV that allow these cells to be partially 
permissive. Such experiments might involve generating clonal lines of THP-1 cells, selecting 
clonal lines that are more permissive, and characterizing changes in gene expression that 
correlate with changes in permissiveness. Additional experiments might attempt to identify 
regions of the major-group HRV16 genome that confer this virus with the ability to replicate in 
leukemic monocyte-lineage cell lines. Such experiments might involve gain-of-function 
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passaging experiments, in which HRV16 is grown in THP-1 cells for multiple rounds of 
replication, thereby selecting for genetic changes that allow HRV to replicate more successfully 
in these cells. After such directed evolution experiments, the HRV16 genome could be sequenced 
and compared to the parent strain, thereby revealing regions of the HRV16 genome that are 
important for growth in monocyte-lineage cells. These changes could then be introduced into the 
minor-group HRV1A genome via gene swap experiments, potentially altering the cellular host 
range of minor-group HRV. Such experiments would be a natural corollary to the capsid gene 
swap experiments discussed herein (Figure 10), and similar experiments have been performed 
successfully by others(156).
Significance and conclusions
Over the course of the experiments described herein, it has been shown that major-group  
HRV, but not minor-group HRV, replicate in a subset of monocyte-lineage cells, particularly in 
cell lines of leukemic origin. Neither major- nor minor-group HRV were found to replicate in 
primary human macrophages, and the replication of these viruses was not found to be sensitive to 
the presence of type I interferon or to the expression of a subset of interferon-stimulated genes. 
Although no definitive mechanism controlling the cellular tropism of HRV in monocyte-lineage 
cells was identified, these studies do suggest that positive- and negative-sense HRV RNA 
accumulate in monocyte-lineage cells even when these cells are non-permissive, which may 
contribute to this mechanism. Future work will characterize the molecular mechanisms 
responsible for the limited HRV replicative capacity offered by monocyte-lineage cells; once 
molecular mechanisms that restrict HRV replication in these cells are more fully understood, this 
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information may contribute to the development of anti-HRV therapeutics, which would be of 
benefit to individuals with chronic conditions such as asthma and COPD, for whom common 
colds caused by HRV can severely exacerbate symptoms to the point of becoming life 
threatening. Such therapeutics would likely be aimed at recapitulating the conditions restricting 
HRV replication in monocyte-lineage cells in cells that are normally permissive, such as the 
epithelial cells of the upper and lower respiratory tract.
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